

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/100533/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Serpi, Michaela , De Biasi, Roberto, Pertusati, Fabrizio , Slusarczyk, Magdalena and McGuigan, Christopher 2017. Synthetic approaches for the preparation of phosphoramidate prodrugs of 2'-deoxypseudoisocytidine. *ChemistryOpen* 6 (3) , pp. 424-436. 10.1002/open.201700019

Publishers page: <http://dx.doi.org/10.1002/open.201700019>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Synthetic Approaches for the Preparation of Phosphoramidate Prodrugs of 2'-Deoxypseudoisocytidine

Michaela Serpi,^{*[a]} Roberto De Biasi,^[a, b] Fabrizio Pertusati,^[a] Magdalena Slusarczyk,^[a] and Christopher McGuigan^[a]

In memory of Prof. Christopher McGuigan

A synthetic procedure for the preparation of phosphoramidate prodrugs of C-nucleosides is reported. Different phosphorochloridates were reacted with 3'-O-protected *N*-acetyl-2'-deoxypseudoisocytidine or 3'-O-protected 2'-deoxypseudoisocytidine, followed by acidic hydrolysis of the protecting group. In the presence of the *N*-acetyl moiety, the enolisable keto group of the nucleobase was able to react (like the 5'-OH) with the phosphorochloridates to give bisphosphorylated derivatives. Epimerisation (β to α) occurred if the amino group of the nu-

cleobase was unprotected. These side reactions demonstrate the peculiar behaviour of C-nucleosides compared to their nucleoside analogues. It was demonstrated that the first enzymatic activation step for this new class of prodrugs can be mediated by carboxypeptidase and that it follows the same pathway and rate reported for ProTides of more conventional nucleoside analogues. These new phosphoramidate derivatives deserve further investigation for their therapeutic potential as anti-cancer agents.

1. Introduction

The C-nucleosides represent a group of nucleoside analogues in which the sugar moiety is linked to the nucleobase by a carbon-carbon bond.^[1] Several C-nucleosides are naturally occurring compounds. Among them, pseudouridine was the first to be isolated from yeast tRNA in 1957.^[2] Subsequently, other C-nucleosides, including oxazinomycin,^[3] pyrazomycin,^[3] showdomycin,^[4] and formycin A,^[5] were isolated from culture filtrates of different bacterial strains. These compounds are antibiotics and exhibit anti-cancer and/or antiviral activity. Their advantageous properties arise from the presence of a C-C glycosidic bond, which gives a greater resistance than *N*-nucleosides towards chemical hydrolysis and enzymatic hydrolysis by phosphorylase and deaminase enzymes. On the basis of these interesting chemical and biological properties, a wide variety of synthetic analogues have been prepared thanks to the large array of novel synthetic methodologies developed in the last two decades. Several of these compounds have found numerous applications in medicinal chemistry and chemical biology.^[1]

Among them, pseudoisocytidine (PIC, **1**), a nucleoside isostere of cytidine was developed as a candidate for anti-leukaemic therapy^[6] (Figure 1). PIC was shown to be incorporated into both RNA and DNA and this incorporation was considered to be responsible for its therapeutic activity, which has been observed against several mouse leukaemias *in vitro* and *in vivo*.^[7,8] In addition, PIC was found to disrupt DNA methylation by inhibition of the enzyme DNA methyltransferase, most probably due to the presence of a nitrogen atom in the 5-position of the base.^[9] However, the development of PIC was halted due to hepatotoxicity observed during phase I clinical evaluation.^[10] The efficiency with which PIC is incorporated into RNA, and the rapid RNA turnover, associated with protein synthesis in the liver, were considered the main causes of its hepatotoxicity. This finding prompted the investigation of 2'-deoxypseudoisocytidine (2'-d-PIC, **2**),^[11] which, in preliminary tissue culture experiments, was found to exhibit inhibitory activity against P815 cell lines.^[11a] PIC, 2'-d-PIC and their analogues were also used as novel base-pairing agents in oligonucleotides to investigate DNA and RNA structures and functions.^[12] Although several C-nucleoside analogues have been described as anti-cancer and/or antiviral agents, none have ever been developed as anti-cancer or antiviral drugs. The recent advent of two novel C-nucleosides, BCX4430 (**3**)^[13] and GS-6620 (**4**),^[14] as potential therapeutic agents for the treatment of the Ebola virus and hepatitis C virus (HCV) infections, respectively, has stimulated renewed interest in this class of compounds (Figure 1).

As part of our current research we were interested to further investigate the potential utility of 2'-d-PIC (**2**) as an anti-leukaemic agent by preparing a series of phosphoramidate prodrugs for biological evaluation as anti-cancer agents. "ProTides" in

[a] Dr. M. Serpi, R. De Biasi, Dr. F. Pertusati, Dr. M. Slusarczyk, Prof. C. McGuigan
School of Pharmacy and Pharmaceutical Sciences, Cardiff University
King Edward VII Avenue, Cardiff CF10 3NB (UK)
Fax: (+44) 02920874537
E-mail: serpim5@cardiff.ac.uk

[b] R. De Biasi
Dipartimento di Scienze Farmaceutiche
Università degli Studi di Perugia
Via del Liceo 1, 06123 Perugia (Italy)

© 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.





Figure 1. Structures of pseudouridine (PIC, **1**), 2'-deoxypseudouridine (2'-d-PIC, **2**), BCX4430 (**3**), GS-6620 (**4**), sofosbuvir (**5**), tenofovir alafenamide (TAF, **6**), NUC-1031 (**7**), and NUC-3373 (**8**).

the clinic have consistently showed greater efficacy and more favourable safety profiles relative to the corresponding standard-of-care nucleoside analogues. Several pharmaceutical companies have already validated the phosphoramidate approach for antiviral applications. In 2014, Gilead launched on the market its anti-HCV ProTide, sofosbuvir (**5**)^[15] and in the following year tenofovir alafenamide (TAF, **6**),^[16] an anti-HIV ProTide (Figure 1). NuCana introduced the ProTide technology to clinical oncology with NUC-1031 (**7**),^[17] a ProTide of gemcitabine, and NUC-3373 (**8**),^[18] a ProTide of 2'-deoxy-5-fluorouridine, currently in phase III and phase I clinical studies, respectively, for patients with advanced solid tumours (Figure 1).

2. Results and Discussion

2.1. Synthesis of 2'-Deoxypseudouridine (2)

Several approaches have been developed for the preparation of C-glycosides^[19] and C-nucleosides.^[20] Among them, for the synthesis of 2'-d-PIC (**2**), we selected the methodology developed by Daves et al., which utilises a Pd-catalysed Heck-type coupling of aryl halides to cyclic enol ethers, either pyranoid or furanoid glycols.^[21] As outlined in Scheme 1, the protected furanoid glycol **12** and the halogenated *N*-acetyl pseudouridine **11**, served as starting materials for the Heck reaction. 2-*N*-Acetyl-5-iodoisocytosine (**11**) was synthesised in good yield in two steps from commercially available isocytosine (**9**), which was first iodinated with *N*-iodosuccinimide in acetic acid to afford the intermediate compound **10**. Subsequent acetylation



Scheme 1. Synthesis of 2'-d-PIC (**2**). NIS, *N*-iodosuccinimide; BSA, Bis(trimethylsilyl)acetamide; DIPEA, *N,N*-diisopropylethylamine.

of the exocyclic amino function of **10** using acetic anhydride yielded the desired nucleobase **11**.^[22] Compound **12** was prepared from 3',5'-bis-*O*-(*tert*-butyldimethylsilyl)thymidine^[23] by using typical silylation conditions first reported by Pedersen et al.^[24] and then applied by Hammer et al.^[25] for the preparation of furanose glycols with a wide range of *O*-silyl protections.


The coupling reaction of 5-iodo base **11** with the protected ribofuranosyl glycol **12** using Pd(OAc)₂ as a catalyst, AsPh₃ as a soft ligand and *N,N*-diisopropylethylamine as a base, formed selectively the β-*C*-nucleoside **13**. After removal of the silyl groups with fluoride ions, the resulting 2'-deoxy-3'-keto *C*-nucleoside **14** was treated with sodium triacetoxyborohydride to reduce diastereoselectively the 3'-keto group from the β-face of the furanosyl ring, forming *N*-acetyl-2'-deoxypseudoisocytidine **15**.^[22] The cleavage of the acetyl group to afford nucleoside **2** was then accomplished by basic hydrolysis using NH₃ in MeOH. The assignment of the configuration at the 1'-position of **2** was based on the comparison of its ¹H NMR spectrum with that reported in the literature.^[22]

2.2. Synthesis of *N*-Acetyl-2'-deoxypseudoisocytidine Phosphoramidates

The two synthetic strategies commonly used for the preparation of phosphoramidate prodrugs (phosphorochloridate in the presence of either *tert*-butylmagnesium chloride or *N*-methylimidazole as a base)^[26] failed when applied to **2**, probably due to the low solubility of the starting material in the reaction medium, returning only unreacted starting materials. Attempts to improve the solubility of **2** using different solvents were unsuccessful. Application of the ProTide approach to precursors **14** and **15** also failed, indicating that development of a suitable synthetic strategy to afford phosphoramidates of **2** was more challenging than originally expected. These results prompted us to use a different synthetic methodology with compound **17** as the key intermediate (Scheme 2).

We envisaged that introduction of a *tert*-butyldimethylsilyl ether at the 3'-OH group in **15** would help to improve its solubility and to achieve exclusive phosphorylation at the 5'-position.

In order to prepare compound **17**, the two hydroxy groups of deoxyribose present in *N*-acetyl-2'-deoxypseudoisocytidine (**15**) were first protected with a *tert*-butyldimethylsilyl group using *tert*-butyldimethylsilyl chloride in DMF for 24 h at room temperature in the presence of 4-dimethylaminopyridine (DMAP) to provide, after flash chromatography, compound **16** in reasonable yield. Then, selective silyl group deprotection was achieved with aqueous trifluoroacetic acid to give, after isolation by silica gel chromatography, **17** with a free primary hydroxy group in moderate yield. Next, phosphorochloridates **18a-f**, prepared as a mixture of *R_p* and *S_p* diastereoisomers according to a literature procedure,^[26] were reacted with **17** in the presence of *tert*-butylmagnesium chloride (1.0 M in THF), yielding 3'-*O*-*tert*-butyldimethylsilyl phosphoramidates **20a-f** (Scheme 2) as diastereomeric mixtures after column chromatography, except for **20d**, which was isolated after purification as a single diastereoisomer. Despite the almost complete consumption of the starting material, the desired products **20a-f** were recovered in low yields, which was ascribed in each case to the formation of a bisphosphorylated by-product, as exemplified in Figure 2. The bisphosphorylated compound **19f** was isolated and its structure was characterised by mass spectrometry and ³¹P and ¹H NMR analysis,^[31] which clearly suggested that the phosphorylation involved the oxygen atom of the pyrimidine ring rather than either one of the nitrogen atoms. *N*-Acetylisocytidine possesses an enolisable keto group which, like the 5'-OH group, is able to react with a phosphorochloridate to give an *O*-phosphorylated derivative. In support of this result, we found in the literature that the reaction of 2-acetylamino-4-hydroxypyrimidines with phosphorochloridates gives *O*-phosphoryl rather than *N*-phosphoryl derivatives.^[27] The substantial steric requirement of the phosphoryl chloride and the steric hindrance exerted to some extent by the acetyl group



Scheme 2. Synthesis of ProTides **21 a-f**. TBDMSCl, *tert*-butyldimethylsilyl chloride; DMAP, 4-dimethylaminopyridine; TFA, trifluoroacetic acid.




Figure 2. Proposed rationale for the *O*-phosphorylation side reaction.

were considered to be the key features for preventing phosphorylation at either one of the ring nitrogen atoms.^[27]

Acidic deprotection of **20a–f** afforded after preparative HPLC purification compounds **21a–f** in moderate yields (Scheme 2 and Table 1). Attempts to remove the acetyl protec-

Cmpd	Ar	R	Yield [%]	d.r.	Cmpd	Yield [%]	d.r.
20a	Ph	CH ₂ Ph	25	1.5:1	21a	50	2.3:1
20b	Ph	(CH ₂) ₅ CH ₃	21	1.5:1	21b	60	1.5:1
20c	Ph	(CH ₂) ₄ CH ₃	28	1:1	21c	16	1:1
20d	Naph	CH(CH ₃) ₂	12	1:0	21d	37	1:0
20e	Naph	CH ₂ C(CH ₃) ₃	13	1:1	21e	46	2.3:1
20f	Naph	CH ₂ Ph	59	1.5:1	21f	25	4:1

tion from **21a** with Schwartz's reagent as described by Ferrari et al.,^[28] failed due to the ring opening of the base. The difficulties encountered in removing the *N*-acetyl group from **21a–f** using mild conditions, and the fact that the labile P–O bond of the ProTide would not tolerate other harsh de-acetylating agents such as methanolic ammonia, prompted us to abandon our attempts toward modification of **21a–f**. We therefore continued our effort to conceive a more efficient route that would allow the preparation of the *N*-deacetylated analogues.


2.3. Synthesis of 2'-Deoxypseudoisocytidine Phosphoramidates

As shown in Scheme 3, compound **22**, obtained by treatment of **16** with methanolic ammonia, underwent selective 5'-desilylation using aqueous trifluoroacetic acid in THF to afford the monosilyl compound **23** in excellent yield. Next, phosphorochloridates **18a** and **18g** were reacted with **23** in the presence of *tert*-butylmagnesium chloride (1.0 M in THF) to yield, after column chromatography, the 3'-*O*-*tert*-butyldimethylsilyl-protected phosphoramidates **24a** and **24g** in moderate yield as diastereoisomeric mixtures (Table 2). No traces of bisphosphorylated products either due to *O*- or *N*-phosphorylation were observed.

Table 2. Reaction outcomes for the synthesis of **24a** and **24g** and ProTides **25a** and **25g** after HPLC purification.


Cmpd	Ar	R	d.r.	Yield [%]	Cmpd	Yield [%]	d.r.
24a	Ph	CH ₂ Ph	2.3:1	41	25a	62	1:0
24g	Ph	CH(CH ₃) ₂	1:3	32	25g	50	4:1

Acidic deprotection of the *tert*-butyldimethylsilyl moieties in **24a** and **24g** with trifluoroacetic acid in dichloromethane (1:2 v/v; room temperature, overnight), afforded the final compounds **25a** and **25g** as mixtures of α and β isomers in a 3:1 ratio after column chromatography. The β -isomers of **25a** and



Scheme 3. Synthesis of ProTides **25a** and **25g**.

25 g were isolated in low yield after preparative HPLC purification (**25 a** as a single diastereoisomer and **25 g** as a mixture; Scheme 3 and Table 2). Most probably, the presence of a dissociable proton on N-1 facilitates the α,β -epimerisation in acidic conditions through a ring opening–closure of the carbohydrate ring (Scheme 4) as previously reported for other C-nucleosides.^[11b,c,29]



Scheme 4. Proposed mechanism for the epimerisation of C-nucleoside phosphoramidates under acidic conditions.

If a mild procedure for the cleavage of *tert*-butyldimethylsilyl ethers to alcohols (based on an exchange reaction with trimethylsilyl triflate at $-78\text{ }^{\circ}\text{C}$)^[30] was used, no epimerisation was observed.

2.4. Enzymatic Studies on the Activation of C-Nucleoside ProTides

To exert their biological activity, ProTides must be metabolised *in vivo* into the monophosphate form, which in turn generates the active triphosphate form by two consecutive phosphorylation reactions.^[31] In the process of intracellular activation of ProTides, the first step is catalysed by a carboxylesterase-type enzyme, such as cathepsin A, which was shown to be responsible for the cleavage of the amino acid ester moiety.^[32] In order to demonstrate that the ProTides of C-nucleosides are activated in a similar manner, the interaction of compound **21 e** with a carboxylesterase-type enzyme was investigated. Carboxypeptidase Y was used as a surrogate of cathepsin A because it belongs to the same family of C-type carboxypeptidases and it was reported to share similarities in the active site.^[33]

Compound **21 e** in $[\text{D}_6]$ acetone was therefore incubated in an NMR tube with carboxypeptidase Y in Trizma buffer (pH 7.6), and the progress of the reaction was monitored by ^{31}P NMR analysis over 14 h. The stacked spectra (Figure 3) show the formation of a new peak after 10 min of incubation, which corresponds to intermediate **I** ($\delta_{\text{p}}=5.06$ ppm, $t=10$ min). Complete conversion of the ProTide **21 e** (which in $[\text{D}_6]$ acetone appears as a single peak at $\delta_{\text{p}}=4.26$ ppm) into the corresponding aminoacyl phosphoramidate ester (**II**: $\delta_{\text{p}}=$




Figure 3. Deconvoluted ^{31}P NMR spectra (202 MHz, $[\text{D}_6]$ acetone/pH 7.6 Trizma buffer) to show the carboxypeptidase-mediated activation of compound **21 e**.

7.19 ppm) was observed in 40 min. *In vivo*, the aminoacyl phosphoramidate ester metabolite is then believed to undergo P–N bond cleavage, mediated by a phosphoramidase-type enzyme to eventually release the parent drug in its monophosphate form.

3. Conclusions

An alternative route to C-nucleoside ProTides has been developed and used to prepare phosphoramidate derivatives of 2'-d-PIC (**2**) and *N*-acetyl 2'-d-PIC (**15**). Unexpected side reactions such as phosphorylation of the enolisable keto group of the nucleobase and epimerisation through ring opening highlighted the different reactivity of C-nucleosides compared to nucleoside analogues. The first carboxypeptidase-mediated bioactivation step for this new class of prodrugs followed the same pathway and rate as reported for ProTides of conventional nucleoside analogues. Biological evaluation of these novel nucleoside analogues should enhance our understanding of the potential of C-nucleosides as anti-tumour agents and in particular of 2'-d-PIC as an anti-leukaemic drug. Together with derivatives **25 a** and **25 g**, we plan to evaluate the *N*-acetylated derivatives **21 a–f** for their anti-tumour activity. We considered that the acetyl moiety would further enhance the lipophilicity of these compounds and remove the potential for their protonation *in vitro*, whereas *in vivo* the acetyl moiety would most probably be able to undergo cleavage (thus acting as a dual prodrug). The results of these investigations will be disclosed in due course.

Experimental Section

Chemistry

All anhydrous solvents were purchased from Sigma–Aldrich and amino acid esters from Novabiochem. All commercially available reagents were used without further purification.

Precoated aluminium-backed plates (60F₂₅₄, 0.2 mm thickness, Merck) were used for thin-layer chromatography (TLC) and were visualised under both short- and long-wavelength UV light (254 and 366 nm, respectively). Flash column chromatography was performed using silica gel supplied by Fisher (60 A, 35–70 μm). Analytical HPLC analysis was performed using either a ThermoScientific or a Varian Prostar system. ¹H (500 MHz), ¹³C (125 MHz), and ³¹P NMR (202 MHz) spectra were recorded on a Bruker Avance 500 MHz spectrometer at 25 °C. Chemical shifts (δ) are quoted in parts per million (ppm) relative to internal references CD₃OD (δ = 3.34 ppm, ¹H NMR; δ = 49.86 ppm, ¹³C NMR) and CDCl₃ (δ = 7.26 ppm, ¹H NMR; δ = 77.4 ppm, ¹³C NMR), or external 85% H₃PO₄ (δ = 0.00 ppm, ³¹P NMR). Coupling constants (*J*) are expressed in Hertz. The following abbreviations are used in the assignment of NMR signals: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), brs (broad singlet), dd (doublet of doublet), dt (doublet of triplet). Low-resolution mass spectrometry was performed on a Bruker Daltons micrOTOF–LC system.

For practical purposes, in some cases standard procedures are given. Procedures that differ from the standard are fully described.

N-(6-Oxo-1,6-dihydropyrimidin-2-yl)acetamide (10)

N-Iodosuccinimide (22.0 g, 98 mmol) was added to a solution of 2-aminopyrimidin-4(3*H*)-one (**9**, 10.0 g, 90 mmol) in acetic acid (170 mL) at 70 °C. The resulting suspension was heated at 100 °C and stirred for 1 h. The reaction mixture was cooled to room temperature and H₂O (500 mL) was added. The solid was filtered, washed with H₂O and dried with a heat gun at 50 °C for 12 h to afford compound **10** as a light pink solid (12.8 g, 60% yield). ¹H NMR (500 MHz, DMSO): δ = 11.24 (brs; NH), 7.93 (s, 1H; *H*-6), 6.69 ppm (s, 2H; NH₂).

N-(5-Iodo-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide (11)

A suspension of **10** (11.8 g, 49.8 mmol) and acetic anhydride (11.8 mL, 124.5 mmol) in DMF (200 mL) was heated to 100 °C. After 1.5 h the clear solution was evaporated to dryness under high vacuum and the residue was suspended in EtOH. The solid was filtered off and washed with Et₂O to afford **11** as a white solid (9.2 g, 66% yield). ¹H NMR (500 MHz, DMSO): δ = 12.15 (s, 1H; NH), 11.74 (brs; NH), 8.31 (s, 1H; *H*-6), 2.16 ppm (s, 3H; CH₃); ¹³C NMR (125 MHz, DMSO): δ = 173.5 (C=O), 166.4 (C-4), 152.2 (C-2), 150.8 (C-6), 81.3 (C-5), 23.0 ppm (COCH₃).

N-(5-((2*R*,5*R*)-4'-[(*tert*-Butyldimethylsilyloxy)-5'-[(*tert*-butyldimethylsilyloxy)methyl]-2',5'-dihydrofuran-2-yl]-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide (13)

N,O-Bis(trimethylsilyl)-acetamide (9 mL, 7.5 g, 37 mmol) was added dropwise to a suspension of **11** (8.0 g, 29 mmol) in DMF (50 mL) under an argon atmosphere. After stirring for 1 h the reaction became a clear solution. Then *N,N*-diisopropylethylamine (6.3 mL, 4.67 g, 36 mmol) and 1,4-anhydro-3,5-*O*-bis(*tert*-butyldimethylsilyl)-2-deoxy-*D*-erythro-pent-1-enitol (**12**, 4.0 g, 11.6 mmol) were added. In a separate flask, Pd(OAc)₂ (0.5 g, 2.2 mmol) was added to a solution of triphenylarsine (1.3 g, 4.2 mmol) in stirring DMF (100 mL). After 30 min, this solution was added slowly to the first flask and the mixture was stirred for 24 h at 80 °C. The reaction was quenched with the addition of H₂O (30 mL) and the solvent was evaporated under reduced pressure. The residue was redissolved in EtOAc (500 mL), and washed with H₂O (2 × 200 mL) and brine

(200 mL). The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane 7:3) to give **13** as a light yellow solid (2.8 g, 52% yield). ¹H NMR (500 MHz, CDCl₃): δ = 12.30 (brs, 1H; NH), 9.86 (brs, 1H; NH), 8.04 (s, 1H; *H*-6), 5.75 (s, 1H; *H*-1'), 4.92 (s, 1H; *H*-2'), 4.53–4.51 (m, 1H; *H*-4'), 3.84 (dd, *J* = 11.5, 2.5 Hz, 1H; *H*-5'a), 3.69 (dd, *J* = 11.5, 4.0 Hz, 1H; *H*-5'b), 0.92 (s, 9H; C(CH₃)₃), 0.90 (s, 9H; C(CH₃)₃), 0.09 (s, 6H; Si(CH₃)₂), 0.02 ppm (s, 6H; Si(CH₃)₂); ¹³C NMR (125 MHz, CD₃OD): δ = 174.2 (C=O), 161.3 (C-4), 151.4 (C-6), 148.1 (C-2), 123.0 (C-5), 101.3 (C-2'), 85.4 (C-4'), 77.9 (C-1') 64.7 (C-5'), 26.5 (SiC(CH₃)₃), 26.1 (SiC(CH₃)₃), 22.5 (COCH₃), 19.4 (SiC(CH₃)₃), 18.8 (SiC(CH₃)₃), –6.1 (Si(CH₃)₂), –6.3 ppm (Si(CH₃)₂); MS (ES⁺): *m/z* (%): 496 [M+H]⁺ (40), 518.26 [M+Na]⁺ (100).

N-[(5-[(2*R*,4*S*,5*R*)-4'-Hydroxy-5'-(hydroxymethyl)tetrahydrofuran-2'-yl]-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide (15)

70% HF–pyridine (2.9 mL) was added dropwise to a solution of **13** (3.0 g, 6.0 mmol) in THF (100 mL). The reaction was stirred at room temperature for 12 h under an argon atmosphere. The suspension was diluted with acetic acid (30 mL) and the volatiles removed under reduced pressure to obtain crude compound **14**, which was used in the next step without further purification. ¹H NMR (500 MHz, CD₃OD): δ = 8.1 (s, 1H; *H*-6), 5.17 (dd *J* = 10.2, 6.8 Hz 1H; *H*-1'), 4.04 (t, *J* = 3.5 Hz, 1H; *H*-4'), 3.65 (dd, *J* = 12.2, 2.6 Hz, 1H; *H*-5'a), 3.61 (dd, *J* = 12.2, 3.5 Hz, 1H; *H*-5'b), 2.89–2.86 (m, 1H; *H*-2'a), 2.53–2.50 (m, 1H; *H*-2'b), 2.23 ppm (s, 3H; CH₃); MS (ESI, negative-ion mode): *m/z*: found 266.20 [M–H]⁺ 100%; reversed-phase HPLC, eluting with H₂O/CH₃CN from 98/2 to 0/100 in 45 min, flow = 1 mL min^{–1}, λ = 254 nm, t_R = 7.75 min.

The residue was dissolved in a mixture of acetic acid/CH₃CN (1:1 v/v, 200 mL) and the mixture was cooled to –15 °C, followed by the portionwise addition of NaBH(OAc)₃ (3.0 g, 14.1 mmol). After 2 h, the mixture was evaporated to dryness under reduced pressure and the residue was purified by flash column chromatography (CH₂Cl₂/CH₃OH 8:2) to give **15** as a white solid (1.3 g, 80% yield). ¹H NMR (500 MHz, [D₆]DMSO): δ = 12.09 (brs, 1H; NH), 11.73 (brs, 1H; NH), 8.1 (s, 1H; *H*-6), 5.14 (brs, 1H; 5'-OH), 4.95–4.90 (m, 1H; *H*-1'), 4.09 (t, *J* = 3.3 Hz, 1H; *H*-4'), 3.65 (ddd, *J* = 12.0, 4.2, 2.5 Hz, 1H; *H*-5'a), 3.61 (ddd, *J* = 12.5, 7.3, 2.5 Hz, 1H; *H*-5'b), 3.17 (d, *J* = 5.4 Hz, 1H; 3'-OH), 2.76 (dd, *J* = 17.6, 6.6 Hz, 1H; *H*-2'a), 2.42 (dd, *J* = 17.5, 10.0 Hz, 1H; *H*-2'b), 2.16 ppm (s, 3H; CH₃); ¹³C NMR (125 MHz, CD₃OD): δ = 175.1 (C=O), 159.6 (C-4), 153.6 (C-6), 152.7 (C-2), 123.4 (C-5), 88.9 (C-4'), 75.7 (C-1'), 73.4 (C-3'), 64.1 (C-5'), 41.7 (C-2'), 23.9 ppm (CH₃); MS (ES⁺): *m/z* (%): calcd for C₁₁H₁₅N₃O₅: 269 [M]; found: 291.09 [M+Na]⁺ (100); reversed-phase HPLC, eluting with H₂O/CH₃OH from 90:10 to 0:100 in 30 min, flow = 1 mL min^{–1}, λ = 254 nm, t_R = 4.87 min.

2-Amino-5-[(2*R*,4*S*,5*R*)-4'-hydroxy-5'-(hydroxymethyl)tetrahydrofuran-2'-yl]pyrimidin-4(3*H*)-one (2)

Ammonia in MeOH (7 mL, 1 mL) was added to a stirred solution of **15** (20.0 mg, 0.074 mmol) in MeOH (0.2 mL) at 0 °C under an argon atmosphere. After 30 min, the mixture was allowed to reach room temperature and was stirred for a further 6 h. The volatiles were removed under reduced pressure and the crude material was purified by preparative reversed-phase HPLC (eluting with H₂O/CH₃OH from 100/0 to 0/100 over 30 min, flow rate 20 mL min^{–1}) to give **2** as a white solid (12.0 mg, 71% yield). ¹H NMR (500 MHz, CD₃OD): δ = 7.68 (s, 1H; *H*-6), 5.00 (s, 1H; *H*-1'), 4.33 (d *J* = 5.6 Hz, 1H; *H*-3'),

3.94–3.92 (m, 1H; *H-4'*), 3.83 (dd, *J* = 12.2, 3.6 Hz, 1H; *H-5'a*), 3.63 (dd, *J* = 12.7, 4.0 Hz, 1H; *H-5'b*), 2.23–2.17 (m, 1H; *H-2'a*), 2.10 ppm (dd, *J* = 13.0, 6.0 Hz, 1H; *H-2'b*); ¹³C NMR (125 MHz, CD₃OD): δ = 166.1 (C-4), 156.3 (C-2), 148.6 (C-6), 114.6 (C-5), 87.5 (C-4'), 76.0 (C-1'), 73.4 (C-3'), 62.6 (C-5'), 40.3 ppm (C-2'); MS (ES⁺): *m/z* (%): 228.04 [*M* + *H*]⁺ (50), 250.01 [*M* + *Na*]⁺ (100); reversed-phase HPLC, eluting with H₂O/CH₃OH from 90:10 to 0:100 in 30 min, flow = 1 mL min⁻¹, λ = 254 nm, t_R = 4.57 min.

N-[5-((2*R*,4*S*,5*R*)-4'-[(*tert*-Butyldimethylsilyloxy)-5'-[(*tert*-butyldimethylsilyloxy)methyl]tetrahydrofuran-2'-yl]-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide (16)

Imidazole (0.4 g, 5.8 mmol), *tert*-butyldimethylsilyl chloride (0.44 g, 2.9 mmol) and DMAP (0.04 g, 0.33 mmol) were added to a solution of **15** (0.34 g, 1.26 mmol) in DMF (2.5 mL) at room temperature under an argon atmosphere and the reaction was stirred at room temperature for 24 h. The reaction mixture was then quenched with CH₃OH (1 mL) and the solvent was removed under reduced pressure. The residue was diluted with CH₂Cl₂ (5 mL) and washed with H₂O (2 mL), NaHCO₃ (2 mL) and brine (2 mL). The organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (EtOAc/hexane 7:3) to give **16** as a white solid (0.410 g, 65% yield). ¹H NMR (500 MHz, CD₃OD): δ = 7.85 (s, 1H; *H-6*), 4.98 (dd, *J* = 9.0, 5.5 Hz, 1H; *H-1'*), 4.32–4.30 (m, 1H; *H-3'*), 3.78–3.76 (m, 1H; *H-4'*), 3.64 (dd, *J* = 10.5, 4.5 Hz, 1H; *H-5'a*), 3.56 (dd, *J* = 10.5, 4.5 Hz, 1H; *H-5'b*), 2.21–2.16 (m, 1H; *H-2'a*), 2.10 (s, 3H; CH₃), 1.79–1.69 (m, 1H; *H-2'b*), 0.83 (s, 9H; C(CH₃)₃), 0.81 (s, 9H; C(CH₃)₃), 0.02 (s, 3H; Si(CH₃)₂), 0.02 (s, 3H; Si(CH₃)₂), 0.01 (s, 3H; Si(CH₃)₂), 0.00 ppm (s, 3H; Si(CH₃)₂); ¹³C NMR (125 MHz, CD₃OD): δ = 173.6 (C=O), 159.6 (C-4), 151.0 (C-6), 148.4 (C-2), 123.1 (C-5), 87.6 (C-4'), 74.1 (C-1', C-3'), 63.4 (C-5'), 40.9 (C-2'), 25.1 (C(CH₃)₃), 25.0 (C(CH₃)₃), 22.5 (COCH₃), 17.8 (C(CH₃)₃), 17.5 (C(CH₃)₃), -5.8 (Si(CH₃)₂), -5.9 (Si(CH₃)₂), -6.6 (Si(CH₃)₂), -6.7 ppm (Si(CH₃)₂); MS (ES⁺): *m/z* (%): 498.3 [*M* + *H*]⁺ (50), 519.2 [*M* + *Na*]⁺ (100).

N-(5-((2*R*,4*S*,5*R*)-4'-[(*tert*-Butyldimethylsilyloxy)-5'-(hydroxymethyl)tetrahydrofuran-2'-yl]-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide (17)

A mixture of TFA and H₂O (1:1 v/v, 2.4 mL) was added dropwise to a solution of **16** (0.3 g, 0.6 mmol) in THF (4.8 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 h under an argon atmosphere, then quenched with aqueous NaHCO₃; CH₂Cl₂ was added and the aqueous phase was extracted twice with CH₂Cl₂. The combined organic layers were dried over MgSO₄, filtered and concentrated under vacuum to yield **17** as a glassy solid (0.172 g, 75%), which was used in the next step without further purification. ¹H NMR (500 MHz, CD₃OD): δ = 7.92 (s, 1H; *H-6*), 4.94 (dd, *J* = 9.0, 5.5 Hz, 1H; *H-1'*), 4.45–4.42 (m, 1H; *H-3'*), 3.75 (dt, *J* = 4.5, 2.5 Hz, 1H; *H-4'*), 3.68 (dd, *J* = 11.9, 4.5 Hz, 1H; CH_{2a-5'}), 3.66 (dd, *J* = 11.9, 4.5 Hz, 1H; CH_{2b-5'}), 2.30–2.14 (m, 1H; CH_{2a-2'}), 2.22 (s, 3H; CH₃), 2.12–1.99 (m, 1H; CH_{2b-2'}), 0.95 (s, 9H; C(CH₃)₃), 0.02 (s, 3H; Si(CH₃)₂), 0.01 ppm (s, 3H; Si(CH₃)₂); ¹³C NMR (125 MHz, CD₃OD): δ = 173.5 (C=O), 160.3 (C-4), 149.9 (C-6), 148.2 (C-2), 123.0 (C-5), 87.5 (C-4'), 83.7 (C-1'), 74.2 (C-3'), 71.0 (C-5'), 39.4 (C-2'), 25.0 (SiC(CH₃)₃), 22.5 (COCH₃), 17.7 (SiC(CH₃)₃), -5.9 (Si(CH₃)₂), -6.6 ppm (Si(CH₃)₂); MS (ES⁺): *m/z* (%): 384.2 [*M* + *Na*]⁺ (100); reversed-phase HPLC, eluting with H₂O/CH₃OH from 90:10 to 0:100 in 30 min, flow = 1 mL min⁻¹, λ = 254 nm, t_R = 16.37 min.

Standard Procedure 1: Synthesis of Phosphorochloridates 18a–g

Anhydrous triethylamine (2.0 mol equiv.) was added dropwise at -78 °C to a stirred solution of the appropriate amino ester hydrochloride/tosylate salt (1.0 mol equiv.) and the appropriate dichlorophosphate (1.0 mol equiv.) in anhydrous dichloromethane (61.6 mol) under an argon atmosphere. After 1 h the reaction mixture was allowed to warm to room temperature and was stirred for an additional 1–2 h. Formation of the desired phosphorochloridate was monitored by ³¹P NMR spectroscopy. After the reaction was completed, the solvent was removed under reduced pressure and the resulting residue was re-dissolved in anhydrous diethyl ether and the triethylammonium salt was removed by filtration. The filtrate was evaporated to dryness and the crude material was purified by flash column chromatography with ethyl acetate/hexane (1:1 v/v) as the eluent to give the desired phosphorochloridate as an oil.

Phenyl-(benzoxy-L-alaninyl)-phosphorochloridate (18a)

Prepared according to standard procedure 1 in 92% yield. ¹H NMR (500 MHz, CDCl₃): δ = 7.30–7.10 (m, 10H; *H-Ar*), 5.20–5.16 (m, 2H; OCH₂Ph), 4.25–4.22 (m, 1H; CHCH₃), 3.51–3.48 (m, 1H; NH), 1.54 (d, *J* = 7.3 Hz, 1.5H; CHCH₃), 1.52 ppm (d, *J* = 7.3 Hz, 1.5H; CHCH₃); ¹³C NMR (125 MHz, CDCl₃): δ = 169.8 (d, *J*_{C-P} = 5.4 Hz; C=O), 135.0 (d, *J*_{C-P} = 6.8 Hz; *ipso*-C-Ph), 134.7 (C-*ipso*-OCH₂Ph), 130.0, 129.8, 129.6, 128.7, 128.7, 128.4, 128.3, 126.0 (CH-Ph), 120.6 (d, *J*_{C-P} = 2.5 Hz; CH-Ph), 120.5 (d, *J*_{C-P} = 2.5 Hz; CH-Ph), 68.1, 67.7 (OCH₂Ph), 50.8, 50.5 (CHCH₃), 20.5 ppm (d, *J* = 5.6 Hz; CHCH₃); ³¹P NMR (202 MHz, CDCl₃): δ = 7.93 (0.5P), 7.51 ppm (0.5P).

Phenyl-(hexoxy-L-alaninyl)-phosphorochloridate (18b)

Prepared according to standard procedure 1 in 87% yield. ¹H NMR (500 MHz, CDCl₃): δ = 7.24–7.18 (m, 5H; *H-Ph*), 4.34–4.20 (m, 1H; NH), 4.20–4.05 (m, 3H; CHCH₃ and OCH₂), 4.03–3.94 (m, 2H; OCH₂CH₂), 1.66–1.56 (m, 4H; OCH₂CH₂CH₂CH₂), 1.59–1.53 (m, 3H; CHCH₃), 1.37–1.31 (m, 4H; CH₂CH₂CH₃), 0.94–0.87 ppm (CH₂CH₃); ¹³C NMR (125 MHz, CDCl₃): δ = 172.8 (d, *J*_{C-P} = 7.8 Hz; C=O), 172.7 (d, *J*_{C-P} = 7.8 Hz; C=O), 149.8 (d, *J*_{C-P} = 8.0 Hz; *ipso*-C-Ph), 149.8 (d, *J*_{C-P} = 8.0 Hz; *ipso*-C-Ph), 129.9, 129.8, 125.9, 125.9 (CH-Ph), 120.6 (d, *J*_{C-P} = 5.3 Hz; CH-Ph), 66.0, 65.9 (OCH₂), 50.8, 50.5 (CHCH₃), 31.3 (OCH₂CH₂), 28.4 (OCH₂CH₂CH₂), 25.4 (OCH₂CH₂CH₂CH₂), 22.5 (CH₂CH₃), 22.4 (d, *J*_{C-P} = 5.6 Hz; CHCH₃), 22.3 (d, *J*_{C-P} = 5.6 Hz; CHCH₃), 13.9 ppm (CH₂CH₃); ³¹P NMR (202 MHz, CDCl₃): δ = 7.96 (0.5P), 7.64 ppm (0.5P).

Phenyl-(pentoxy-L-alaninyl)-phosphorochloridate (18c)

Prepared according to standard procedure 1 in 96% yield. ¹H NMR (500 MHz, CDCl₃): δ = 7.46–7.31 (m, 2H; *H-Ph*), 7.28–7.22 (m, 3H; *H-Ph*), 4.68 (brs; NH), 4.18–4.09 (m, 3H; OCH₂, CHCH₃), 1.73–1.71 (m, 2H; OCH₂CH₂), 1.68–1.65 (m, 5H; OCH₂CH₂CH₂, CHCH₃), 1.36–1.32 (m, 2H; CH₂CH₃), 0.92–0.89 ppm (m, 3H; CH₃); ¹³C NMR (125 MHz, CDCl₃): δ = 172.7 (d, *J*_{C-P} = 7.7 Hz; C=O), 172.6 (d, *J*_{C-P} = 7.3 Hz; C=O), 149.6 (d, *J*_{C-P} = 8.1 Hz; *ipso*-C-Ph), 149.4 (d, *J*_{C-P} = 8.0 Hz; *ipso*-C-Ph), 129.9, 129.8, 125.9, 125.8 (CH-Ph), 120.5 (d, *J*_{C-P} = 5.5 Hz, CH-Ph), 65.9, 65.8 (OCH₂), 50.5, 50.3 (CHCH₃), 31.3 (OCH₂CH₂), 28.3 (OCH₂CH₂CH₂), 22.4 (CH₂CH₃), 22.4 (d, *J* = 5.8 Hz, CHCH₃), 22.4 (d, *J* = 5.7 Hz, CHCH₃), 13.9 ppm (7CH₂CH₃); ³¹P NMR (202 MHz, CDCl₃): δ = 7.92 (0.5P), 7.61 ppm (0.5P).

1-Naphthyl-(isopropoxy-L-alaninyl)-phosphorochloridate (18 d)

Prepared according to standard procedure 1 in 84% yield. ¹H NMR (500 MHz, CDCl₃): δ = 8.10–8.07 (m, 1H; CH-Naph), 7.88–7.82 (m, 1H; CH-Naph), 7.76–7.56 (m, 1H; H-Naph), 7.6–7.3 (m, 4H; H-Naph), 5.13–5.09 (m, 1H; OCH(CH₃)₂), 4.54 (brs, 1H; NH), 4.26–4.22 (m, 1H; CHCH₃), 1.56 (d, *J* = 7.0 Hz, 1.5H; CHCH₃), 1.54 (d, *J* = 7.0 Hz, 1.5H; CHCH₃), 1.34–1.25 ppm (m, 6H; OCH(CH₃)₂); ¹³C NMR (125 MHz, CDCl₃): δ = 173.1 (C=O), 149.8 (d, *J*_{C-P} = 8.0 Hz; ipso-C-Ph), 147.3 (ipso-C-Ph), 134.9, 134.8 (C-Naph), 129.0, 127.6, 126.9, 126.7, 126.3 (CH-Naph), 126.1 (d, *J*_{C-P} = 8.3 Hz; C-Naph), 125.5, 124.4, 122.0, 121.5, 121.4, 121.3, 116.2, 116.1, 115.2 (CH-Naph), 70.6, 69.2 (OCH(CH₃)₂), 51.0, 50.7 (CHCH₃), 21.7, 21.5 (CHCH₃), 16.1 ppm (OCH(CH₃)₂); ³¹P NMR (202 MHz, CDCl₃): δ = 8.35 (0.5 P), 8.03 ppm (0.5 P).

1-Naphthyl-(2,2-dimethyl-propoxy-L-alaninyl)-phosphorochloridate (18 e)

Prepared according to standard procedure 1 in 91% yield. ¹H NMR (500 MHz, CDCl₃): δ = 8.20–7.30 (m, 7H; H-Naph), 4.48–4.34 (brs, 1H; NH), 4.38–4.20 (m, 1H; CHCH₃), 3.90–3.70 (m, 2H; CH₂C(CH₃)₃), 1.58–1.45 (m, 3H; CHCH₃), 0.89 (s, 4.5H; C(CH₃)₃), 0.87 ppm (s, 4.5H; C(CH₃)₃); ¹³C NMR (125 MHz, CDCl₃): δ = 171.7 (d, *J*_{C-P} = 2.5 Hz; C=O), 171.6 (d, *J*_{C-P} = 2.5 Hz; C=O), 146.7 (d, *J*_{C-P} = 6.3 Hz; ipso-C-Naph), 134.7 (C-Naph), 128.9, 129.0, 127.9, 126.9, 126.8, 126.2 (CH-Naph), 126.1 (d, *J*_{C-P} = 8.7 Hz; C-Naph), 125.9, 121.4, 121.3 (CH-Naph), 75.2 (CH₂C(CH₃)₃), 75.1 (CH₂C(CH₃)₃), 50.9 (CHCH₃), 50.6 (CHCH₃), 26.4 (C(CH₃)₃), 26.3 (C(CH₃)₃), 20.9 ppm (d, *J* = 4.8 Hz, CHCH₃); ³¹P NMR (202 MHz, CDCl₃): δ = 8.25 (0.5 P), 7.95 ppm (0.5 P).

1-Naphthyl-(benzoxy-L-alaninyl)-phosphorochloridate (18 f)

Prepared according to standard procedure 1 in 78% yield. ¹H NMR (500 MHz, CDCl₃): δ = 8.12–7.97 (m, 1H; H-Naph), 7.73–7.57 (m, 1H; H-Naph), 7.65–7.32 (m, 10H; H-Ar), 5.25–5.21 (m, 2H; OCH₂Ph), 4.81–4.78 (m, 1H; NH), 4.23–4.20 (m, 1H; CHCH₃), 1.59–1.57 ppm (m, 3H; CHCH₃); ¹³C NMR (125 MHz, CDCl₃): δ = 173.9 (d, *J*_{C-P} = 6.5 Hz; C=O), 173.8 (d, *J*_{C-P} = 6.5 Hz; C=O), 146.8 (d, *J*_{C-P} = 6.3 Hz; ipso-C-Naph), 135.4, 134.8 (C-Naph), 128.6, 128.4, 128.2, 128.1, 126.7, 126.5, 126.3, 126.0 (d, *J*_{C-P} = 8.2 Hz; C-Naph), 125.7, 124.4, 121.5, 115.2, 115.2 (CH-Ph, CH-Naph), 67.1 (OCH₂Ph), 50.2 (CHCH₃), 50.1 (d, *J*_{C-P} = 2.0 Hz; CHCH₃), 21.1 (d, *J* = 5.3 Hz; CHCH₃), 21.0 ppm (d, *J* = 5.3 Hz; CHCH₃); ³¹P NMR (202 MHz, CDCl₃): δ = 8.19 (0.5 P), 7.94 ppm (0.5 P).

Phenyl-(isopropoxy-L-alaninyl)-phosphorochloridate (18 g)

Prepared according to standard procedure 1 in 93% yield. ¹H NMR (500 MHz, CDCl₃): δ = 7.41–7.36 (m, 2H; H-Ph), 7.31–7.27 (m, 3H; H-Ph), 5.21–5.01 (m, 1H; OCH(CH₃)₂), 4.65 (brs, 1H; NH), 4.21–4.06 (m, 1H; CHCH₃), 1.51 (d, *J* = 7.0 Hz, 3H; CHCH₃), 1.26–1.19 ppm (m, 6H; OCH(CH₃)₂); ¹³C NMR (125 MHz, CD₃OD): δ = 172.2 (d, *J*_{C-P} = 8.2 Hz; C=O), 172.1 (d, *J*_{C-P} = 9.1 Hz; C=C=O), 149.8 (d, *J*_{C-P} = 8.4 Hz; ipso-C-Ph), 149.8 (d, *J*_{C-P} = 8.3 Hz; ipso-C-Ph), 129.9 (CH-Ph), 126.0 (CH-Ph), 120.5 (d, *J*_{C-P} = 5.4 Hz; CH-Ph), 69.8, 69.8 (OCH(CH₃)₂), 50.9, 50.6 (CHCH₃), 21.6, 21.5 (OCH(CH₃)₂), 20.4 (d, *J*_{C-P} = 4.3 Hz; CHCH₃), 20.6 ppm (d, *J*_{C-P} = 4.3 Hz; CHCH₃); ³¹P NMR (202 MHz, CDCl₃): δ = 8.08 (0.5 P), 7.71 ppm (0.5 P).

Standard Procedure 2: Synthesis of 20 a–f, 24 a and 24 g

A solution of *t*BuMgCl in THF (1.0 M, 1.2 mol equiv.) was added at 0 °C to a stirred solution of **17** or **23** (1 mol equiv.) in THF. The reaction mixture was allowed to warm to room temperature and the appropriate phosphorochloridate (2.0 mol equiv.) dissolved in anhydrous THF was added. The reaction mixture was stirred for 16–18 h and then evaporated under vacuum to give a crude residue that was purified by column chromatography on silica gel, eluting with a gradient of CH₃OH (0–5%) in CH₂Cl₂ to afford products **20 a–f**, **24 a** and **24 g** as white solids.

(2S)-Benzyl 2-((((2'R,3'S,5'R)-5-(2-Acetamido-6-oxo-1,6-dihydropyrimidin-5-yl)-3-[(tert-butyl dimethylsilyl)oxy]tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino}propanoate (20 a)

Prepared according to standard procedure 2 from nucleoside **17** (0.048 g, 0.137 mmol), **18 a** (0.088 g, 0.27 mmol) in anhydrous THF (2.4 mL) and *t*BuMgCl in THF (1 M, 0.16 mL). After workup, the crude product was purified by column chromatography on silica gel using CH₂Cl₂/CH₃OH (95:5) as eluent to provide **20 a** as a white solid (22 mg, 25% yield). ¹H NMR (500 MHz, CD₃OD): δ = 7.89 (s, 1H; H-6), 7.35–7.32 (m, 7H; H-Ar), 7.22–7.14 (m, 3H; H-Ar), 5.18–5.00 (m, 3H; H-1', OCH₂Ph), 4.40–4.39 (m, 1H; H-3'), 4.21–4.12 (m, 2H; CH₂-5'), 4.05–4.00 (m, 2H; H-4', CHCH₃), 2.33–2.23 (m, 1H; CH_{2a}-2'), 2.21 (s, 1.2H; COCH₃), 2.20 (s, 1.8H; COCH₃), 1.81–1.71 (m, 1H; CH_{2b}-2') 1.37 (d, *J* = 7.1 Hz, 1.2H; CHCH₃), 1.36 (d, *J* = 7.2 Hz, 1.2H; CHCH₃), 0.92 (s, 9H; C(CH₃)₃), 0.11 (s, 1.5H; Si(CH₃)₂), 0.10 (s, 1.5H; Si(CH₃)₂), 0.09 ppm (s, 3H; Si(CH₃)₂); ³¹P NMR (202 MHz, CD₃OD): δ = 3.89 (0.6 P), 3.48 ppm (0.4 P); MS (ES⁺): *m/z* (%): 701 [M + H]⁺ (30), 723.30 [M + Na]⁺ (100).

(2S)-Hexyl 2-((((2'R,3'S,5'R)-5-(2-Acetamido-6-oxo-1,6-dihydropyrimidin-5-yl)-3-[(tert-butyl dimethylsilyl)oxy]tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino}propanoate (20 b)

Prepared according to standard procedure 2 from nucleoside **17** (0.090 g, 0.256 mmol), **18 b** (0.177 g, 0.512 mmol) in anhydrous THF (2.4 mL) and *t*BuMgCl in THF (1 M, 0.30 mL). After workup, the crude was purified by column chromatography on silica gel with CH₂Cl₂/CH₃OH (95:5) as eluent to provide **20 b** as a solid (34 mg, 21% yield). ¹H NMR (500 MHz, CD₃OD): δ = 7.90 (s, 1H; H-6), 7.36–7.31 (m, 2H; H-Ph), 7.24–7.15 (m, 3H; H-Ph), 5.11–5.04 (m, 1H; H-1'), 4.44–4.42 (m, 1H; H-3'), 4.26–4.17 (m, 2H; CH₂-5'), 4.10–4.13 (m, 2H; OCH₂), 4.04–4.03 (m, 1H; H-4'), 4.00–3.94 (m, 1H; CHCH₃), 2.33–2.26 (m, 1H; CH_{2a}-2'), 2.23 (s, 1.5H; COCH₃), 2.22 (s, 1.5H; COCH₃), 1.86–1.78 (m, 1H; CH_{2b}-2'), 1.70–1.63 (OCH₂CH₂), 1.38–1.28 (m, 9H; (CH₂)₃CH₃, CHCH₃), 0.93 (s, 4.5H; C(CH₃)₃), 0.92 (s, 4.5H; C(CH₃)₃), 0.92–0.88 (m, 3H; CH₂CH₃), 0.11 (s, 1.5H; Si(CH₃)₂), 0.11 (s, 1.5H; Si(CH₃)₂), 0.10 ppm (s, 3H; Si(CH₃)₂); ³¹P NMR (202 MHz, CD₃OD): δ = 3.80 (0.6 P), 3.48 ppm (0.4 P); MS (ES⁺): *m/z* (%): 695.85 [M + H]⁺ (30), 717.50 [M + Na]⁺ (100).

(2S)-Pentyl 2-((((2'R,3'S,5'R)-5-(2-Acetamido-6-oxo-1,6-dihydropyrimidin-5-yl)-3-[(tert-butyl dimethylsilyl)oxy]tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino}propanoate (20 c)

Prepared according to standard procedure 2 from nucleoside **17** (0.100 g, 0.284 mmol), **18 c** (0.189 g, 0.568 mmol) in anhydrous THF (2.6 mL) and *t*BuMgCl in THF (1 M, 0.33 mL). After workup, the

crude material was purified by column chromatography on silica gel with $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ (95:5) as the eluent to provide **20c** as a solid (50 mg, 28% yield). ^1H NMR (500 MHz, CD_3OD): δ = 7.88 (s, 1H; *H*-6), 7.33–7.28 (m, 2H; *H*-Ph), 7.21–7.12 (m, 3H; *H*-Ph), 5.14–5.06 (m, 1H; *H*-1'), 4.40–4.38 (m, 1H; *H*-3'), 4.25–4.16 (m, 2H; CH_2 -5'), 4.13–4.10 (m, 2H; OCH_2), 4.03–4.00 (m, 1H; *H*-4'), 4.00–3.94 (m, 1H; CHCH_3), 2.35–2.28 (m, 1H; $\text{CH}_{2\alpha}$ -2'), 2.25 (s, 3H; COCH_3), 1.86–1.75 (m, 1H; $\text{CH}_{2\beta}$ -2'), 1.73–1.70 (m, 2H; OCH_2CH_2), 1.69–1.65 (m, 5H; $\text{OCH}_2\text{CH}_2\text{CH}_2$, CHCH_3), 1.36–1.32 (m, 2H; CH_2CH_3), 0.94 (s, 4.5H; $\text{C}(\text{CH}_3)_3$), 0.92 (s, 4.5H; $\text{C}(\text{CH}_3)_3$), 0.91–0.89 (m, 3H; CH_2CH_3), 0.11 (s, 1.5H; $\text{Si}(\text{CH}_3)_2$), 0.11 (s, 1.5H; $\text{Si}(\text{CH}_3)_2$), 0.10 ppm (s, 3H; $\text{Si}(\text{CH}_3)_2$); ^{31}P NMR (202 MHz, CD_3OD): δ = 3.85 (0.5P), 3.56 ppm (0.5P); MS (ES^+): m/z (%): 681.8 [$M+H$] $^+$ (30), 703.50 [$M+Na$] $^+$ (100).

(2S)-Isopropyl 2-((((2'R,3'S,5'R)-5-(2-Acetamido-6-oxo-1,6-dihydropyrimidin-5-yl)-3'-((tert-butyl dimethylsilyl)oxy)tetrahydrofuran-2'-yl)methoxy)(naphthalen-1-yloxy)phosphoryl]amino]propanoate (20d)

Prepared according to standard procedure 2 from nucleoside **17** (0.180 g, 0.47 mmol), **18d** (0.335 g, 0.94 mmol) in anhydrous THF (2.4 mL) and *t*BuMgCl in THF (1 M, 0.56 mL). After workup, the crude material was purified by column chromatography on silica gel with $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ (95:5) as the eluent to provide **20d** as a solid (40 mg, 12% yield). ^1H NMR (500 MHz, CD_3OD): δ = 8.13–8.10 (m, 1H; *H*-Naph), 7.85–7.81 (m, 2H; *H*-Naph, *H*-6), 7.71–7.67 (m, 1H; *H*-Naph), 7.56–7.15 (m, 4H; *H*-Naph), 5.10–4.90 (m, 2H; *H*-1', $\text{OCH}(\text{CH}_3)_2$), 4.25–4.10 (m, 3H; CH_2 -5', *H*-3'), 4.05–3.94 (m, 2H; CHCH_3 , *H*-4'), 2.26–2.15 (m, 1H; $\text{CH}_{2\alpha}$ -2'), 2.23 (s, 3H; COCH_3), 2.01–1.98 (m, 1H; $\text{CH}_{2\beta}$ -2'), 1.38–1.34 (m, 3H; CHCH_3), 1.21 (s, 6H; $\text{CH}(\text{CH}_3)_2$), 0.86 (s, 9H; $\text{C}(\text{CH}_3)_3$), 0.018 (s, 3H; $\text{Si}(\text{CH}_3)_2$), 0.00 ppm (s, 3H; $\text{Si}(\text{CH}_3)_2$); ^{31}P NMR (202 MHz, CD_3OD): δ = 4.31 ppm (1P); MS (ES^+): m/z (%): 703.40 [$M+H$] $^+$ (30), 725.40 [$M+Na$] $^+$ (100); reversed-phase HPLC, eluting with $\text{H}_2\text{O}/\text{CH}_3\text{CN}$ from 90:10 to 0:100 in 30 min, flow = 1 mL min^{-1} , λ = 254 nm, t_R = 24.85 min.

(2S)-Neopentyl 2-((((2'R,3'S,5'R)-5-(2-Acetamido-6-oxo-1,6-dihydropyrimidin-5-yl)-3'-((tert-butyl dimethylsilyl)oxy)tetrahydrofuran-2'-yl)methoxy)(naphthalen-1-yloxy)phosphoryl]amino]propanoate (20e)

Prepared according to standard procedure 2 from nucleoside **17** (0.172 g, 0.45 mmol), **18e** (0.345 g, 0.9 mmol) in anhydrous THF (2.3 mL) and *t*BuMgCl in THF (1 M, 0.54 mL). After workup, the crude material was purified by column chromatography on silica gel with $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ (94:6) as the eluent to provide **20e** as a solid (42.0 mg, 13% yield). ^1H NMR (500 MHz, CD_3OD): δ = 7.94 (d, J = 8.6 Hz, 0.5H; *H*-Naph), 7.82 (d, J = 8.6 Hz, 0.5H; *H*-Naph), 7.78–7.63 (m, 2H; *H*-Naph, *H*-6), 7.50–7.21 (m, 5H; *H*-Naph), 4.98 (dd, J = 10.0, 5.5 Hz, 0.5H; *H*-1'), 4.90 (dd, J = 10.0, 5.5 Hz, 0.5H; *H*-1'), 4.26–4.21 (m, 1H; *H*-3'), 4.12–4.06 (m, 2H; CH_2 -5'), 3.75–3.71 (m, 1H; CHCH_3), 3.70–3.58 (m, 2H; $\text{CH}_2\text{C}(\text{CH}_3)_3$), 3.39–3.31 (m, 1H; *H*-4'), 2.12 (s, 1.5H; COCH_3), 2.13–2.08 (m, 1H; $\text{CH}_{2\alpha}$ -2'), 2.09 (s, 1.5H; COCH_3), 2.03–1.98 (m, 1H; $\text{CH}_{2\beta}$ -2'), 1.28 (d, J = 7.0 Hz, 1.5H; CHCH_3), 1.25 (d, J = 7.0 Hz, 1.5H; CHCH_3), 0.81 (s, 4.5H; $\text{C}(\text{CH}_3)_3$), 0.79 (s, 4.5H; $\text{C}(\text{CH}_3)_3$), 0.00 (s, 3H; $\text{Si}(\text{CH}_3)_2$), –0.031 (s, 1.5H; $\text{Si}(\text{CH}_3)_2$), –0.039 ppm (s, 1.5H; $\text{Si}(\text{CH}_3)_2$); ^{31}P NMR (202 MHz, CD_3OD): δ = 4.30 (0.5P), 3.91 ppm (0.5P); MS (ES^+): m/z (%): 731.32 [$M+H$] $^+$ (30), 753.30 [$M+Na$] $^+$ (100); reversed-phase HPLC, eluting with $\text{H}_2\text{O}/\text{CH}_3\text{CN}$ from 90:10 to 0:100 in 30 min, flow = 1 mL min^{-1} , λ = 254 nm, t_R = 17.93 min.

(2S)-Benzyl 2-((((2'R,3'S,5'R)-5-(2-Acetamido-4-((((S)-1-(benzyl-oxy)-1-oxopropan-2-yl]amino}(naphthalen-1-yloxy)phosphoryl)oxy]pyrimidin-5-yl)-3'-((tert-butyl dimethylsilyl)oxy)tetrahydrofuran-2'-yl)methoxy)(naphthalen-1-yloxy)phosphoryl]-L-alaninate (19f) and (2S)-Benzyl 2-((((2'R,3'S,5'R)-5-(2-Acetamido-6-oxo-1,6-dihydropyrimidin-5-yl)-3'-((tert-butyl dimethylsilyl)oxy)tetrahydrofuran-2'-yl)methoxy)(naphthalen-1-yloxy)-phosphoryl]amino]propanoate (20f)

Prepared according to standard procedure 2 from nucleoside **17** (0.095 g, 0.248 mmol), **18f** (0.200 g, 0.495 mmol) in anhydrous THF (4 mL) and *t*BuMgCl in THF (1 M, 0.37 mL). After workup, the crude material was purified by column chromatography on silica gel with $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ (98:2) as the eluent to provide **19f** as a solid (56 mg, 21% yield). ^1H NMR (500 MHz, CDCl_3): δ = 8.90 (brs, 1H; *NH*), 8.88 (brs, 1H; *NH*), 8.55 (s, 0.3H; *H*-6), 8.49 (s, 0.3H; *H*-6), 8.44 (s, 0.4H; *H*-6), 7.81–7.17 (m, 22H; *H*-Naph, *H*-Ph), 5.14–4.94 (m, 5H; $2 \times \text{OCH}_2\text{Ph}$, *H*-1'), 4.47–3.94 (m, 5H; *H*-3', CH_2 -5', $2 \times \text{CHCH}_3$), 3.78–3.79 (m, 1H; *H*-4'), 2.22 (s, 1.5H; COCH_3), 2.18 (s, 0.8H; COCH_3), 2.22 (s, 0.7H; COCH_3), 2.08–2.013 (m, 0.5H; CH_2 -2'), 1.88–1.86 (m, 0.5H; CH_2 -2'), 1.79–1.74 (m, 0.5H; CH_2 -2'), 1.65–1.59 (m, 0.5H; CH_2 -2'), 0.90 (s, 2.3H; $\text{C}(\text{CH}_3)_3$), 0.88 (s, 2.3H; $\text{C}(\text{CH}_3)_3$), 0.87 (s, 4.6H; $\text{C}(\text{CH}_3)_3$), 0.07 (s, 1H; $\text{Si}(\text{CH}_3)_2$), 0.05 (s, 1H; $\text{Si}(\text{CH}_3)_2$), 0.15 (s, 1H; $\text{Si}(\text{CH}_3)_2$), 0.00 (s, 2H; $\text{Si}(\text{CH}_3)_2$), –0.02 ppm (s, 1H; $\text{Si}(\text{CH}_3)_2$); ^{31}P NMR (202 MHz, CD_3OD): δ = 3.96 (0.25P), 3.81 (0.25P), 3.25 (0.5P), 3.19 (0.7P), 3.06 ppm (0.3P); MS (ES^+): m/z (%): 1120.32 [$M+H$] $^+$ (60), 1142.30 [$M+Na$] $^+$ (100).

Further elution of the crude mixture with $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ (95:5) yielded **20f** as a solid (98 mg, 59% yield). ^1H NMR (500 MHz, CD_3OD): δ = 8.10 (d, J = 8.6 Hz, 1H; *H*-Naph), 7.87 (d, J = 8.6 Hz, 1H; *H*-Naph), 7.72–7.62 (m, 2H; *H*-Naph; *H*-6), 7.53–7.39 (m, 4H; *H*-Naph), 7.32–7.27 (m, 5H; *H*-Ph), 5.12–5.05 (m, 2H; OCH_2Ph), 4.98 (dd, J = 10.0, 5.5 Hz, 1H; *H*-1'), 4.26–4.14 (m, 4H; *H*-3', CH_2 -5', CHCH_3), 3.97–3.92 (m, 1H; *H*-4'), 2.22 (s, 3H; COCH_3), 2.12–2.06 (m, 1H; $\text{CH}_{2\alpha}$ -2'), 1.40–1.06 (m, 4H; $\text{CH}_{2\beta}$ -2', CHCH_3), 0.88 (s, 4.5H; $\text{C}(\text{CH}_3)_3$), 0.87 (s, 4.5H; $\text{C}(\text{CH}_3)_3$), 0.05 (s, 1.5H; $\text{Si}(\text{CH}_3)_2$), 0.03 (s, 1.5H; $\text{Si}(\text{CH}_3)_2$), 0.02 (s, 1.5H; $\text{Si}(\text{CH}_3)_2$), –0.08 ppm (s, 1.5H; $\text{Si}(\text{CH}_3)_2$); ^{31}P NMR (202 MHz, CD_3OD): δ = 4.09 (0.6P), 3.97 ppm (0.4P); MS (ES^+): m/z (%): 751.85 [$M+H$] $^+$ (50), 773 [$M+Na$] $^+$ (100).

Standard Procedure 3: Synthesis of Phosphoramidates 21a–f, 25a and 25g

N-Acetyl-3'-*O*-silyl-pseudoisocytidine phosphoramidates **20a–f** or 3'-*O*-silyl-pseudoisocytidine phosphoramidates **24a** and **24g** were treated with TFA/ CH_2Cl_2 (1:1 v/v) at 0°C. The resulting reaction mixture was stirred at 0°C for 6 h. After the reaction was completed the solvents were evaporated and the residue was purified by preparative HPLC to afford **21a–f** and **25a** and **25g**, respectively.

(2S)-Benzyl 2-((((2'R,3'S,5'R)-5-(2-Acetamido-6-oxo-1,6-dihydropyrimidin-5-yl)-3'-hydroxytetrahydrofuran-2'-yl)methoxy)-(phenoxy)phosphoryl]amino]propanoate (21a)

Prepared according to standard procedure 3 from compound **20a** (0.022 g, 0.031 mmol) and TFA/ CH_2Cl_2 (1:1 v/v, 0.3 mL). After workup, the crude material was purified by preparative HPLC ($\text{H}_2\text{O}/\text{CH}_3\text{CN}$ from 90:10 to 0:100 in 30 min, flow = 20 mL min^{-1} , λ = 280 nm) to yield **21a** as a white solid (9.2 mg, 50% yield). ^1H NMR (500 MHz, CD_3OD): δ = 7.88 (s, 1H; *H*-6), 7.35–7.29 (m, 7H; *H*-Ar),

7.21–7.15 (m, 3H; *H*-Ar), 5.17–5.05 (m, 3H; *H*-1', OCH₂Ph), 4.31–4.30 (m, 1H; *H*-3') 4.25–4.11 (m, 2H; CH₂-5'), 4.05–4.00 (m, 2H; *H*-4', CHCH₃), 2.36–2.30 (m, 1H; CH_{2a}-2'), 2.21 (s, 1.2H; COCH₃), 2.20 (s, 1.8H; COCH₃), 1.81–1.75 (m, 1H; CH_{2b}-2'), 1.37 (d, *J* = 7.1 Hz, 1.2H; CHCH₃), 1.35 ppm (d, *J* = 7.2 Hz, 1.2H; CHCH₃); ¹³C NMR (125 MHz, CD₃OD): δ = 175.0 (COCH₃), 175.0 (COCH₃), 174.9 (d, *J*_{C-P} = 6.13 Hz; COCH₂Ph), 167.6 (C-4), 152.2 (d, *J*_{C-P} = 7.2 Hz; *C*-ipso-Ph), 152.2 (d, *J*_{C-P} = 7.09 Hz; *C*-ipso-Ph), 154.1 (C-6), 152.0 (C-2), 137.2 (*C*-ipso-OCH₂Ph), 130.8, 129.6, 129.6, 129.4, 129.3, 129.3, 129.2 (CH-Ar), 124.2 (C-5), 124.1 (C-5), 121.5 (d, *J*_{C-P} = 4.5 Hz; CH-Ph), 121.6 (d, *J*_{C-P} = 4.5 Hz; CH-Ph), 86.3 (d, *J*_{C-P} = 2.3 Hz; C-4'), 86.2 (d, *J*_{C-P} = 2.3 Hz; C-4'), 75.8 (C-1'), 75.8 (C-1'), 74.0 (C-3'), 73.9 (C-3'), 68.1 (d, *J*_{C-P} = 5.6 Hz, C-5'), 68.2 (d, *J*_{C-P} = 5.6 Hz, C-5'), 67.9 (OCH₂Ph), 67.7 (OCH₂Ph), 51.7 (CHCH₃), 51.6 (CHCH₃), 42.8 (C-2'), 42.0 (C-2'), 23.9 (COCH₃), 20.4 (d, *J*_{C-P} = 7.1 Hz; CHCH₃), 20.4 ppm (d, *J*_{C-P} = 7.4 Hz; CHCH₃); ³¹P NMR (202 MHz, CD₃OD): δ = 3.94 (0.7P), 3.52 ppm (0.3P); MS (ES⁺): *m/z* (%): 587.18 [*M* + H]⁺ (30), 609.53 [*M* + Na]⁺ (100); reversed-phase HPLC, eluting with H₂O/CH₃CN from 90:10 to 0:100 in 30 min, flow = 1 mL min⁻¹, λ = 280 nm, t_R = 12.79.

(2S)-Hexyl 2-((((2'R,3'S,5'R)-5-(2-Acetamido-6-oxo-1,6-dihydropyrimidin-5-yl)-3'-hydroxytetrahydrofuran-2'-yl)methoxy)(phenoxy)phosphoryl)amino]propanoate (21 b)

Prepared according to standard procedure 3 from compound **20 b** (0.034 g, 0.049 mmol) and TFA/CH₂Cl₂ (1:1 v/v, 0.5 mL). After workup, the crude was purified by preparative HPLC (H₂O/CH₃CN from 90:10 to 0:100 in 30 min, flow = 20 mL min⁻¹, λ = 280 nm) to provide **21 b** as a solid (17 mg, 60% yield). ¹H NMR (500 MHz, CD₃OD): δ = 7.90 (s, 1H; *H*-6), 7.37–7.31 (m, 2H; *H*-Ar), 7.24–7.15 (m, 3H; *H*-Ar), 5.12 (dd, *J* = 9.8, 5.6 Hz, 0.7H; *H*-1'), 5.12 (dd, *J* = 9.9, 5.9 Hz, 0.3H; *H*-1'), 4.34–4.32 (m, 1H; *H*-3') 4.29–4.17 (m, 2H; CH₂-5'), 4.13–4.05 (m, 3H, *H*-4'; OCH₂), 4.00–3.93 (m, 1H; CHCH₃), 2.37–2.30 (m, 1H; CH_{2a}-2'), 2.23 (s, 1.2H; COCH₃), 2.22 (s, 1.8H; COCH₃), 1.84–1.79 (m, 1H; CH_{2b}-2') 1.65–1.59 (m, 2H; OCH₂CH₂), 1.40–1.28 (m, 9H; (CH₂)₃CH₃, CHCH₃), 0.94–0.86 ppm (m, 3H; CH₂CH₃); ¹³C NMR (125 MHz, CD₃OD): δ = 175.3 (COCH₃), 175.2 (COCH₃), 175.0 (CO₂-hexyl), 175.0 (CO₂-hexyl), 165.5 (C-4), 152.3 (d, *J*_{C-P} = 6.5 Hz; *C*-ipso-Ph), 152.2 (d, *J*_{C-P} = 7.5 Hz; *C*-ipso-Ph), 154.2 (C-6), 152.1 (C-2), 130.8, 126.2, 126.1 (CH-Ph), 124.2 (C-5), 124.2 (C-5), 121.5 (d, *J*_{C-P} = 4.6 Hz; CH-Ph), 121.5 (d, *J*_{C-P} = 4.7 Hz; CH-Ph), 86.3 (d, *J*_{C-P} = 2.3 Hz; C-4'), 86.3 (d, *J*_{C-P} = 2.3 Hz; C-4'), 75.9 (C-1'), 75.8 (C-1'), 74.1 (C-3'), 73.9 (C-3'), 68.1 (d, *J*_{C-P} = 5.9 Hz; C-5'), 68.3 (d, *J*_{C-P} = 6.2 Hz; C-5'), 66.5 (OCH₂), 66.5 (OCH₂), 51.7 (CHCH₃), 51.6 (CHCH₃), 41.1 (C-2'), 42.0 (C-2'), 32.6, 29.7, 26.6 (CH₂), 23.9 (COCH₃), 23.6 (CH₂CH₃), 20.6 (d, *J*_{C-P} = 6.5 Hz; CHCH₃), 20.5 (d, *J*_{C-P} = 7.3 Hz; CHCH₃), 14.3 ppm (CH₂CH₃); ³¹P NMR (202 MHz, CD₃OD): δ = 3.88 (0.6P), 3.58 ppm (0.4P); MS (ES⁺): *m/z* (%): 581.23 [*M* + H]⁺ (34), 603.57 [*M* + Na]⁺ (100); reversed-phase HPLC, eluting with H₂O/CH₃CN from 90:10 to 0:100 in 30 min, flow = 1 mL min⁻¹, λ = 254 nm, t_R = 15.11.

(2S)-Pentyl 2-((((2'R,3'S,5'R)-5-(2-Acetamido-6-oxo-1,6-dihydropyrimidin-5-yl)-3'-hydroxytetrahydrofuran-2'-yl)methoxy)(phenoxy)phosphoryl)amino]propanoate (21 c)

Prepared according to standard procedure 3 from compound **20 c** (0.050 g, 0.078 mmol) and TFA/CH₂Cl₂ (1:1 v/v, 0.5 mL). After workup, the crude was purified by preparative HPLC (H₂O/CH₃CN from 90:10 to 0:100 in 30 min, flow = 20 mL min⁻¹, λ = 280 nm) to give **21 c** as a solid (6.5 mg, 16% yield). ¹H NMR (500 MHz, CD₃OD): δ = 7.90 (s, 0.5H; *H*-6), 7.85 (s, 0.5H; *H*-6), 7.38–7.29 (m, 2H; *H*-Ar), 7.24–7.15 (m, 3H; *H*-Ar), 5.12 (dd, *J* = 9.8, 5.6 Hz, 0.5H; *H*-1'), 5.09

(dd, *J* = 9.9, 5.9 Hz, 0.5H; *H*-1'), 4.35–4.32 (m, 1H; *H*-3') 4.30–4.21 (m, 2H; CH₂-5'), 4.15–4.05 (m, 3H; *H*-4', OCH₂), 4.00–3.94 (m, 1H; CHCH₃), 2.37–2.31 (m, 1H; CH_{2a}-2'), 2.23 (s, 1.5H; COCH₃), 2.22 (s, 1.5H; COCH₃), 1.84–1.72 (m, 1H; CH_{2b}-2'), 1.64–1.61 (m, 2H; OCH₂CH₂), 1.40–1.28 (m, 9H; (CH₂)₃CH₃, CHCH₃), 0.93–0.91 ppm (m, 3H; CH₂CH₃); ¹³C NMR (125 MHz, CD₃OD): δ = 176.0 (COCH₃), 175.2 (COCH₃), 175.0 (CO₂-pentyl), 175.0 (CO₂-pentyl), 165.5 (C-4), 157.7 (C-6), 152.3 (d, *J*_{C-P} = 6.5 Hz; *C*-ipso-Ph), 152.2 (d, *J*_{C-P} = 7.5 Hz; *C*-ipso-Ph), 152.1 (C-2), 130.6, 126.2, 126.1 (CH-Ph), 124.1 (C-5), 121.5 (d, *J*_{C-P} = 4.6 Hz; CH-Ph), 121.5 (d, *J*_{C-P} = 4.7 Hz; CH-Ph), 86.3 (d, *J*_{C-P} = 2.3 Hz; C-4'), 75.9 (C-1'), 75.8 (C-1'), 74.1 (C-3'), 74.0 (C-3'), 68.3 (d, *J*_{C-P} = 5.9 Hz; C-5'), 68.1 (d, *J*_{C-P} = 6.2 Hz; C-5'), 66.5 (OCH₂), 51.7 (CHCH₃), 51.6 (CHCH₃), 42.0 (C-2'), 29.4, 29.1 (CH₂), 23.9 (COCH₃), 23.4 (CH₂CH₃), 20.6 (d, *J*_{C-P} = 6.5 Hz; CHCH₃), 20.5 (d, *J*_{C-P} = 7.3 Hz; CHCH₃), 14.3 ppm (CH₂CH₃); ³¹P NMR (202 MHz, CD₃OD): δ = 3.92 (0.5P), 3.60 ppm (0.5P); MS (ES⁺): *m/z* (%): 567.20 [*M* + H]⁺ (34), 589.30 [*M* + Na]⁺ (100); reversed-phase HPLC, eluting with H₂O/CH₃CN from 90:10 to 0:100 in 30 min, flow = 1 mL min⁻¹, λ = 254 nm, t_R = 17.44.

(2S)-Isopropyl 2-((((2'R,3'S,5'R)-5-(2-Acetamido-6-oxo-1,6-dihydropyrimidin-5-yl)-3'-hydroxytetrahydrofuran-2'-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)amino]propanoate (21 d)

Prepared according to standard procedure 3 from compound **20 d** (40 mg, 0.057 mmol) and TFA/CH₂Cl₂ (1:1 v/v, 0.3 mL). After workup, the crude was purified by preparative HPLC (H₂O/MeCN from 90:10 to 0:100 in 30 min, flow = 20 mL min⁻¹, λ = 280 nm) to yield **21 d** as a white solid (12.6 mg, 37% yield). ¹H NMR (500 MHz, CD₃OD): δ = 8.10–7.97 (m, 1H; *H*-Naph), 7.75–7.65 (m, 2H; *H*-Naph, *H*-6), 7.59–7.47 (m, 1H; *H*-Naph), 7.41–7.37 (m, 3H; *H*-Naph), 7.32 (d, *J* = 8.12 Hz, 0.75H; *H*-Naph), 7.30 (d, *J* = 8.12 Hz, 0.25H; *H*-Naph), 4.93–4.90 (m, 1H; *H*-1'), 4.85–4.79 (m, 1H; OCH(CH₃)₂), 4.17–4.12 (m, 2H; CH₂-5'), 4.11–4.08 (m, 1H; *H*-3'), 3.94–3.87 (m, 2H; CHCH₃, *H*-4'), 2.16–2.10 (m, 1H; CH_{2a}-2'), 2.12 (s, 3H; COCH₃), 2.08–1.99 (m, 1H; CH_{2b}-2'), 1.24 (d, *J* = 7.5 Hz, 3H; CHCH₃), 1.09 (d, *J* = 6.4 Hz, 3H; OCH(CH₃)₂), 1.08 ppm (d, *J* = 6.5 Hz, 3H, OCH(CH₃)₂); ¹³C NMR (125 MHz, CD₃OD): δ = 173.6 (COCH₃), 173.4 (C=O), 173.1 (C=O), 166.2 (C-4), 154.2 (C-6), 152.2 (C-2), 146.7 (d, *J*_{C-P} = 8.3 Hz; *C*-ipso-Naph), 134.9 (C-Naph), 127.5 (CH-Naph), 126.5 (d, *J*_{C-P} = 5.2 Hz; C-Naph), 126.0, 125.1, 124.6 (CH-Naph), 123.2 (C-5), 121.3 (CH-Naph), 114.9 (d, *J*_{C-P} = 3.6 Hz; CH-Naph), 85.0 (C-4'), 74.4 (C-1'), 72.6 (C-3'), 68.8 (OCH), 66.9 (d, *J*_{C-P} = 5.02 Hz; C-5'), 50.6 (CHCH₃), 40.2 (C-2'), 22.5 (COCH₃), 20.5 (OCH(CH₃)₂), 20.4 (OCH(CH₃)₂), 19.1 (d, *J*_{C-P} = 7.3 Hz; CHCH₃), 19.0 ppm (d, *J*_{C-P} = 7.3 Hz; CHCH₃); ³¹P NMR (202 MHz, CD₃OD): δ = 4.34 ppm; MS (ES⁺): *m/z* (%): 611.20 [*M* + Na]⁺ (100); reversed-phase HPLC, eluting with H₂O/CH₃CN from 90:10 to 0:100 in 30 min, flow = 1 mL min⁻¹, λ = 254 nm, t_R = 18.72 min.

(2S)-Neopentyl 2-((((2'R,3'S,5'R)-5-(2-Acetamido-6-oxo-1,6-dihydropyrimidin-5-yl)-3'-hydroxytetrahydrofuran-2'-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)amino]propanoate (21 e)

Prepared according to standard procedure 3 from compound **20 e** (42 mg, 0.056 mmol) and TFA/CH₂Cl₂ (1:1 v/v, 0.3 mL). After workup, the crude was purified by preparative HPLC (H₂O/CH₃CN from 90:10 to 0:100 in 30 min, flow = 20 mL min⁻¹, λ = 280 nm) to give **21 e** as a solid (16.0 mg, 46% yield). ¹H NMR (500 MHz, CD₃OD): δ = 8.02–7.99 (m, 1H; *H*-Naph), 7.75–7.70 (m, 1H; *H*-Naph), 7.66 (s, 1H; *H*-6), 7.57 (d, *J* = 7.8 Hz, 0.7H; *H*-Naph), 7.52 (d, *J* =

8.4 Hz, 0.3 H; *H*-Naph), 7.40–7.34 (m, 3 H; *H*-Naph), 7.32–7.28 (m, 0.7 H; *H*-Naph), 7.31–7.28 (m, 0.3 H; *H*-Naph), 4.89 (dd, $J=10.1$, 6.2 Hz, 1 H; *H*-1'), 4.20–4.12 (m, 2 H; CH_2 -5'), 4.13–4.07 (m, 1 H; *H*-3'), 4.00–3.96 (m, 1 H; $CHCH_3$), 3.92–3.90 (m, 1 H; *H*-4'), 3.73, 3.66 (AB system, $J=10.5$ Hz, 1 H; $OCH_2C(CH_3)_3$), 3.72, 3.62 (AB system, $J=10.5$ Hz, 1 H; $OCH_2C(CH_3)_3$), 2.16–2.10 (m, 1 H; CH_{2a} -2'), 2.10 (s, 2 H; $COCH_3$), 2.09 (s, 1 H; $COCH_3$), 2.16–2.10 (m, 1 H; CH_{2b} -2'), 1.26 (d, $J=7.18$ Hz, 1.2 H; $CHCH_3$), 1.24 (d, $J=7.3$ Hz, 1.8 H; $CHCH_3$), 0.79 (s, 3 H; $OCH_2C(CH_3)_3$), 0.81 ppm (s, 6 H; $OCH_2C(CH_3)_3$); ^{13}C NMR (125 MHz, CD_3OD): $\delta=173.7$ ($COCH_3$), 171.2 ($COCH_2C(CH_3)_3$), 170.9 ($COCH_2C(CH_3)_3$), 159.2 (C-4), 153.5 (C-6), 152.1 (C-2), 146.7 (d, $J_{C-P}=6.8$ Hz; *C*-*ipso*-Naph), 134.9 (C-Naph), 127.4 (CH-Naph), 126.5 (d, $J_{C-P}=5.2$ Hz, C-Naph), 126.3, 126.1, 125.1, 124.6 (CH-Naph), 123.1 (C-5), 115.0 (d, $J_{C-P}=3.6$ Hz; CH-Naph), 85.0 (C-4'), 74.4 (C-1'), 74.4 (C-1'), 74.4 ($OCH_2C(CH_3)_3$), 72.6 (C-3'), 66.9 (d, $J_{C-P}=5.0$ Hz; C-5'), 66.9 (d, $J_{C-P}=5.0$ Hz; C-5'), 50.5 ($CHCH_3$), 50.5 ($CHCH_3$), 40.8 (C-2'), 30.9 ($OCH_2C(CH_3)_3$), 25.3 ($OCH_2C(CH_3)_3$), 22.5 ($COCH_3$), 19.2 ppm (d, $J_{C-P}=7.3$ Hz; $CHCH_3$). ^{31}P NMR (202 MHz, CD_3OD): $\delta=4.36$ (0.7P), 4.09 ppm (0.3P); MS (ES^+): m/z (%): 639.21 [$M+Na$] $^+$ (100); reversed-phase HPLC, eluting with H_2O/CH_3CN from 90:10 to 0:100 in 30 min, flow = 1 mL min $^{-1}$, $\lambda=254$ nm, $t_R=11.95$ min.

(2S)-Benzyl 2-(((2'R,3'S,5'R)-5-(2-Acetamido-6-oxo-1,6-dihydropyrimidin-5-yl)-3'-hydroxytetrahydrofuran-2'-yl)methoxy)-(naphthalen-1-yloxy)phosphorylamino]propanoate (21 f)

Prepared according to standard procedure 3 from the compound **20 f** (98 mg, 0.130 mmol) and TFA/ CH_2Cl_2 (1:1 v/v, 0.3 mL). After workup, the crude material was purified by preparative HPLC (H_2O/CH_3CN from 90:10 to 0:100 in 30 min, flow = 20 mL min $^{-1}$, $\lambda=280$ nm) to give **21 f** as a white solid (20.1 mg, 25% yield). 1H NMR (500 MHz, CD_3OD): $\delta=8.13$ –8.11 (m, 1 H; *H*-Naph), 7.86–7.84 (m, 2 H; *H*-Naph, *H*-6), 7.71–7.64 (m, 1 H; *H*-Naph), 7.51–7.46 (m, 3 H; *H*-Naph), 7.32 (d, $J=8.12$ Hz, 0.65 H; *H*-Naph), 7.30 (d, $J=8.12$ Hz, 0.35 H; *H*-Naph), 7.33–7.28 (m, 5 H; *H*-Ph), 5.14–5.07 (m, 2 H; OCH_2Ph), 5.03 (dd, $J=8.6$, 5.5 Hz, 1 H; *H*-1'), 4.25–4.20 (m, 3 H; CH_2 -5', *H*-3'), 4.15–4.09 (m, 1 H; $CHCH_3$), 4.03–4.00 (m, 1 H; *H*-4'), 2.21 (s, 3 H; $COCH_3$), 2.19–2.15 (m, 1 H; CH_{2a} -2'), 1.49–1.36 (m, 1 H; CH_{2b} -2'), 1.37 (d, $J=7.5$ Hz, 3 H; $CHCH_3$); ^{13}C NMR (125 MHz, CD_3OD): $\delta=173.6$ ($COCH_3$), 173.6 (C=O), 173.5 (C=O), 166.2 (C-4), 154.2 (C-6), 150.6 (C-2), 146.7 (d, $J_{C-P}=8.3$ Hz; *C*-*ipso*-Naph), 146.6 (d, $J_{C-P}=8.3$ Hz; *C*-*ipso*-Naph), 135.8, 134.9, 134.8 (C-Naph), 128.2, 128.1, 127.9, 127.9, 127.8, 127.4 (CH-Naph), 126.5 (d, $J_{C-P}=5.17$ Hz; C-Naph), 126.4, 126.3, 126.1, 125.1 (CH-Naph), 124.6 (C-5), 124.5 (C-5), 121.3, 121.3 (CH-Naph), 115.1 (d, $J_{C-P}=3.6$ Hz; CH-Naph), 115.0 (d, $J_{C-P}=3.6$ Hz; CH-Naph), 85.1 (C-4'), 85.0 (C-4'), 74.3 (C-1'), 74.2 (C-1'), 72.7 (C-3'), 72.6 (C-3'), 69.0 (d, $J_{C-P}=5.0$ Hz; C-5'), 66.9 (d, $J_{C-P}=5.0$ Hz, C-5'), 66.6 (OCH_2Ph), 66.6 (OCH_2Ph), 50.5 ($CHCH_3$), 50.4 ($CHCH_3$), 40.7 (C-2'), 40.5 (C-2'), 22.5 ($COCH_3$), 19.0 (d, $J_{C-P}=7.3$ Hz; $CHCH_3$), 18.9 ppm (d, $J_{C-P}=7.3$ Hz; $CHCH_3$); ^{31}P NMR (202 MHz, CD_3OD): $\delta=4.33$ (0.8P), 3.98 ppm (0.2P); MS (ES^+): m/z (%): 659.20 [$M+Na$] $^+$ (100); reversed-phase HPLC, eluting with H_2O/CH_3CN from 90:10 to 0:100 in 30 min, flow = 1 mL min $^{-1}$, $\lambda=254$ nm, $t_R=17.45$ min.

2-Amino-5-((2'R,4'S,5'R)-4-[(tert-butylidimethylsilyloxy)-5'-(((tert-butylidimethylsilyloxy)methyl)tetrahydrofuran-2'-yl)pyrimidin-4(3H)-one (22)

Ammonia (7 M) in MeOH (1 mL) was added to a solution of 2-N-acetyl-2'-deoxy-3',5'-O-bis(tert-butylidimethylsilyloxy)pseudocytidine (**16**, 0.55 g, 1.1 mmol) in CH_3OH (5 mL) at 0°C under an argon at-

mosphere. After 30 min the reaction mixture was allowed to warm to room temperature and was stirred for 12 h. The volatiles were removed under vacuum and the crude material was purified by flash column chromatography using CH_2Cl_2/CH_3OH (95:5) as the eluent to give **22** as an oil (0.455 g, 90% yield). 1H NMR (500 MHz, CD_3OD): $\delta=7.54$ (s, 1 H; *H*-6), 4.94 (dd, $J=10.2$, 6.0 Hz, 1 H; *H*-1'), 4.31–4.28 (m, 1 H; *H*-3'), 3.74–3.68 (m, 1 H; *H*-4'), 3.61 (dd, $J=11.0$, 4.0 Hz, 1 H; CH_{2a} -5'), 3.54 (dd, $J=11.0$, 5.5 Hz, 1 H; CH_{2b} -5'), 2.09 (dd, $J=12.5$, 6.0 Hz, 1 H; CH_{2a} -2'), 1.82–1.76 (m, 1 H; CH_{2b} -2'), 0.81 (s, 9 H; $Si(CH_3)_3$), 0.80 (s, 9 H; $Si(CH_3)_3$), 0.02 (s, 3 H; $Si(CH_3)_2$), 0.00 (s, 3 H; $Si(CH_3)_2$), -0.01 (s, 3 H; $Si(CH_3)_2$), -0.02 ppm (s, 3 H; $Si(CH_3)_2$); ^{13}C NMR (125 MHz, CD_3OD): $\delta=165.3$ (C-4), 155.9 (C-2), 128.7 (C-6), 128.7 (C-6), 116.0 (C-5), 87.5 (C-4'), 74.2 (C-1'), 74.1 (C-3'), 63.4 (C-5'), 41.0 (C-2'), 25.1 ($Si(CH_3)_3$), 25.0 ($Si(CH_3)_3$), 17.8 ($Si(CH_3)_3$), 17.5 ($Si(CH_3)_3$), -5.7 ($Si(CH_3)_2$), -5.9 ($Si(CH_3)_2$), -6.6 ($Si(CH_3)_2$), -6.6 ppm ($Si(CH_3)_2$); MS (ES^+): m/z (%): 456.3 [$M+H$] $^+$ (100); reversed-phase HPLC, eluting with H_2O/CH_3CN from 90:10 to 0:100 in 30 min, flow = 1 mL min $^{-1}$, $\lambda=254$ nm, $t_R=19.19$ min.

2-Amino-5-((2'R,4'S,5'R)-4-[(tert-butylidimethylsilyloxy)-5'-(hydroxymethyl)tetrahydrofuran-2'-yl]pyrimidin-4(3H)-one (23)

A mixture of TFA and H_2O (1:1 v/v, 2.0 mL) was added dropwise to a solution of **22** (0.244 g, 0.535 mmol) in THF (4 mL) at 0°C. The reaction was stirred at room temperature for 2 h under an argon atmosphere. The reaction mixture was quenched with $NaHCO_3$ and concentrated under reduced pressure to afford **23** as glassy solid, which was used in the next step without further purification (0.123 g, 67%). 1H NMR (500 MHz, CD_3OD): $\delta=7.61$ (s, 1 H; *H*-6), 4.92 (dd, $J=10.2$, 6.0 Hz, 1 H; *H*-1'), 4.35–4.31 (m, 1 H; *H*-3'), 3.82–3.74 (m, 1 H; *H*-4'), 3.58 (dd, $J=11.5$, 4.5 Hz, 1 H; CH_{2a} -5'), 3.54 (dd, $J=11.5$, 4.5 Hz, 1 H; CH_{2b} -5'), 2.16–2.10 (m, 1 H; CH_{2a} -2'), 1.88–1.82 (m, 1 H; CH_{2b} -2'), 0.85 (s, 9 H; $Si(CH_3)_3$), 0.06 (s, 3 H; $Si(CH_3)_2$), 0.01 ppm (s, 3 H; $Si(CH_3)_2$); ^{13}C NMR (125 MHz, CD_3OD): $\delta=161.3$ (C-4), 150.3 (C-6), 149.8 (C-2), 123.1 (C-5), 88.5 (C-4'), 85.7 (C-1'), 72.2 (C-3'), 70.0 (C-5'), 37.4 (C-2'), 24.0 ($Si(CH_3)_3$), 19.7 ($Si(CH_3)_3$), -6.1 ($Si(CH_3)_2$), -6.4 ppm ($Si(CH_3)_2$); reversed-phase HPLC, eluting with H_2O/CH_3CN from 90:10 to 0:100 in 30 min, flow = 1 mL min $^{-1}$, $\lambda=254$ nm, $t_R=10.8$ min.

(2S)-Benzyl 2-(((2'R,3'S,5'R)-5-(2-Amino-6-oxo-1,6-dihydropyrimidin-5-yl)-3'-[(tert-butylidimethylsilyloxy)tetrahydrofuran-2'-yl]methoxy)(phenoxy)phosphorylamino]propanoate (24 a)

Prepared according to standard procedure 2 from nucleoside **23** (0.035 g, 0.1 mmol), **18 a** (0.071 g, 0.2 mmol) in anhydrous THF (2 mL) and $tBuMgCl$ in THF (1 M, 0.13 mL). After workup, the crude was purified by column chromatography on silica gel using CH_2Cl_2/CH_3OH (92:8) as the eluent to give **24 a** as a solid (0.0223 g, 41%). 1H NMR (500 MHz, CD_3OD): $\delta=7.56$ (s, 1 H; *H*-6), 7.26–7.19 (m, 7 H; *H*-Ph), 7.12–7.06 (m, 3 H; *H*-Ph), 5.07–5.01 (m, 2 H; OCH_2Ph), 4.94 (dd, $J=10.0$, 6.0 Hz, 1 H; *H*-1'), 4.29–4.21 (m, 1 H; *H*-3'), 4.05–4.01 (m, 2 H; CH_2 -5'), 3.96–3.88 (m, 1 H; $CHCH_3$), 3.86–3.83 (m, 1 H; *H*-4'), 2.10–2.06 (m, 0.3 H; *H*-2'a), 2.04–2.01 (m, 0.7 H; *H*-2'a), 1.74–1.79 (m, 1 H; *H*-2'b), 1.29–1.25 (m, 3 H; $CHCH_3$), 0.84 (s, 2.7 H; $Si(CH_3)_3$), 0.82 (s, 6.3 H; $Si(CH_3)_3$), 0.01 (s, 1.8 H; $Si(CH_3)_2$), 0.00 ppm (s, 4.2 H; $Si(CH_3)_2$); ^{31}P NMR (202 MHz, CD_3OD): $\delta=3.79$ (0.7P), 3.49 ppm (0.3P).

(2S)-Isopropyl 2-[[[(2'R,3'S,5'R)-5-(2-Amino-6-oxo-1,6-dihydropyrimidin-5-yl)-3'-[(tert-butyl dimethylsilyloxy)tetrahydrofuran-2'-yl]methoxy](phenoxy)phosphoryl]amino]propanoate (24g)

Prepared according to standard procedure 2 from nucleoside **23** (0.035 g, 0.1 mmol), **18g** (0.067 g, 0.2 mmol) in anhydrous THF (1.5 mL) and tBuMgCl in THF (1 M, 0.13 mL). After workup, the crude material was purified by column chromatography on silica gel using CH₂Cl₂/CH₃OH (92:8) as an eluent to give **24g** as a solid (0.020 g, 32%). ¹H NMR (500 MHz, CD₃OD): δ = 7.56 (brs, 1H; H-6), 7.26–7.22 (m, 2H; H-Ph), 7.14–7.07 (m, 3H; H-Ph), 4.94 (dd, J = 10.0, 6.0 Hz, 1H; H-1'), 4.87–4.79 (m, 1H; OCH(CH₃)₂), 4.38–4.31 (m, 1H; H-3'), 4.12–4.03 (m, 2H; CH₂-5'), 3.89–3.88 (m, 1H; H-4'), 3.83–3.77 (m, 1H; CHCH₃), 2.13–2.00 (m, 1H; CH_{2α}-2'), 1.79–1.69 (m, 1H; CH_{2β}-2'), 1.25 (d, J = 7.0 Hz, 0.7H; CHCH₃), 1.22 (d, J = 7.0 Hz, 2.3H; CHCH₃), 1.14 (d, J = 6.0 Hz, 3H; OCH(CH₃)₂), 1.12 (d, J = 6.0 Hz, 3H; OCH(CH₃)₂), 0.82 (s, 2.3H; Si(CH₃)₃), 0.81 (s, 6.7H; Si(CH₃)₃), 0.02 (s, 0.7H; Si(CH₃)₂), 0.05 (s, 0.7H; Si(CH₃)₂), -0.03 (s, 2.3H; Si(CH₃)₂), -0.07 ppm (s, 2.3H; Si(CH₃)₂); ³¹P NMR (202 MHz, CD₃OD): δ = 3.87 (0.3P), 3.57 ppm (0.7P); reversed-phase HPLC, eluting with H₂O/CH₃CN from 90:10 to 0:100 in 30 min, flow = 1 mL min⁻¹, λ = 254 nm, t_R = 13.42 min.

(2S)-Benzyl 2-[[[(2'R,3'S,5'R)-5-(2-Amino-6-oxo-1,6-dihydropyrimidin-5-yl)-3'-hydroxytetrahydrofuran-2'-yl]methoxy](phenoxy)phosphoryl]amino]propanoate (25a)

Trimethylsilyl trifluoromethanesulfonate (14.5 μL, 0.08 mmol) was added dropwise to a solution of **24a** (22.3 mg, 0.034 mmol) in CH₂Cl₂ (1.5 mL) at -78 °C. The reaction was stirred for 2 h under an argon atmosphere. The solvent was removed under reduced pressure and the crude material was purified by preparative HPLC to yield **25a** as a white solid (11.3 mg, 62%). ¹H NMR (500 MHz, CD₃OD): δ = 7.52 (s, 0.9H; H-6), 7.45 (s, 0.1H; H-6), 7.25–7.18 (m, 7H; H-Ph), 7.09–7.05 (m, 3H; H-Ph), 5.05–4.99 (m, 2H; OCH₂Ph), 4.91 (dd, J = 10.1, 6.1 Hz, 1H; H-1'), 4.22–4.20 (m, 1H; H-3'), 4.13–4.02 (m, 2H; CH₂-5'), 3.97–3.95 (m, 1H; H-4'), 3.91–3.85 (m, 1H; CHCH₃), 2.20 (ddd, J = 13.0, 5.5, 2.0 Hz, 1H; CH₂-2'a), 1.69 (ddd, J = 13.0, 10.0, 6.0 Hz, 1H; CH₂-2'b), 1.28–1.21 ppm (m, 3H; CHCH₃); ¹³C NMR (125 MHz, CD₃OD): δ = 170.4 (COCH₂Ph), 169.9 (COCH₂Ph), 159.7 (C-4), 155.4 (C-6), 152.5 (C-2), 152.1 (d, J_{C-P} = 7.1 Hz; C-*ipso*-Ph), 137.1 (C-*ipso*-OCH₂Ph), 129.5, 129.4, 128.2, 128.0, 127.9, 127.7, 127.6, 125.6 (CH-Ar), 124.8 (C-5), 120.1 (d, J_{C-P} = 4.3 Hz; CH-Ph), 120.1 (d, J_{C-P} = 4.5 Hz; CH-Ph), 85.2 (C-4'), 73.7 (C-1'), 72.6 (C-3'), 72.1 (C-3'), 67.0 (OCH₂Ph), 66.6 (d, J_{C-P} = 5.7 Hz, C-5'), 50.5 (CHCH₃), 40.6 (C-2'), 18.9 (d, J = 5.9 Hz, CHCH₃), 18.9 ppm (d, J = 5.87 Hz, CHCH₃); ³¹P NMR (202 MHz, CD₃OD): δ = 3.93 ppm (1P); MS (ES⁺): m/z (%): 545.2 [M+H]⁺ (100); reversed-phase HPLC, eluting with H₂O/CH₃CN from 90:10 to 0:100 in 30 min, flow = 1 mL min⁻¹, λ = 254 nm, t_R = 9.51 min.

(2S)-Isopropyl 2-[[[(2'R,3'S,5'R)-5-(2-Amino-6-oxo-1,6-dihydropyrimidin-5-yl)-3'-hydroxytetrahydrofuran-2'-yl]methoxy](phenoxy)phosphoryl]amino]propanoate (25g)

Prepared according to standard procedure 3 from compound **24g** (10 mg, 0.016 mmol) and TFA/CH₂Cl₂ (1:1 v/v, 0.6 mL). After workup, the crude material was purified by preparative HPLC to give **25g** as a solid (4.0 mg, 50%). ¹H NMR (500 MHz, CD₃OD): δ = 7.68 (s, 0.8H; H-6), 7.67 (s, 0.2H; H-6), 7.26–7.20 (m, 2H; H-Ph), 7.15–7.02 (m, 3H; H-Ph), 5.07 (dd, J = 10.0, 5.5 Hz, 1H; H-1'), 4.98–

4.96 (m, 1H; OCH(CH₃)₂), 4.33–4.28 (m, 1H; H-3'), 4.23–4.19 (m, 2H; CH₂-5'), 4.05–4.01 (m, 1H; H-4'), 3.92–3.87 (m, 1H; CHCH₃), 2.32–2.20 (m, 2H; CH₂-2'), 1.90–1.80 (m, 2H; CH₂-5'), 1.37 (d, J = 7.0 Hz, 0.6H; CHCH₃), 1.34 (d, J = 7.0 Hz, 2.4H; CHCH₃), 1.25 (d, J = 6.5 Hz, 3H; OCH(CH₃)₂), 1.23 ppm (d, J = 6.5 Hz, 3H; CH(CH₃)₂); ¹³C NMR (125 MHz, CD₃OD): δ = 170.2 (COCH(CH₃)₂), 159.2 (C-4), 153.5 (C-6), 152.1 (C-2), 141.1 (d, J_{C-P} = 4.5 Hz; C-*ipso*-Ph), 129.4, 126.8 (CH-Ph), 123.5 (C-5), 120.2 (d, J_{C-P} = 5.7 Hz; CH-Ph), 120.1 (d, J_{C-P} = 4.5 Hz; CH-Ph), 84.8 (d, J_{C-P} = 8.4 Hz; C-4'), 84.8 (d, J_{C-P} = 8.4 Hz; C-4'), 74.7 (C-1'), 72.8 (C-3'), 68.8 (OCH(CH₃)₂), 66.8 (d, J_{C-P} = 5.7 Hz; C-5'), 50.5 (CHCH₃), 40.5 (C-2'), 39.5 (C-2'), 20.6 (OCH(CH₃)₂), 20.5 (OCH(CH₃)₂), 19.5 (d, J_{C-P} = 7.5 Hz; CHCH₃), 19.0 ppm (d, J_{C-P} = 7.5 Hz; CHCH₃); ³¹P NMR (202 MHz, CD₃OD): δ = 3.91 (0.8P), 3.69 ppm (0.2P); MS (ES⁻): m/z (%): 495.15 [M-H]⁻ (100); reversed-phase HPLC, eluting with H₂O/CH₃CN from 90:10 to 0:100 in 30 min, flow = 1 mL min⁻¹, λ = 254 nm, t_R = 7.75 min.

Carboxypeptidase Y assay

Trizma buffer (300 μL, pH 7.6) was added to compound **21e** (5 mg) dissolved in [D₆]acetone (150 μL). The ³¹P NMR spectrum (202 MHz, 64–128 scans) was recorded at this stage as a reference (blank, t = 0). To this mixture, a stock solution of carboxypeptidase Y (Sigma-Aldrich, > 50 units mg⁻¹, dissolved in pH 7.6 Trizma buffer, to a concentration of 50 units mL⁻¹, EC 3.4.16.1, 130 μL) was added. ³¹P NMR spectra (128 scans) were recorded with a 3 min delay between experiments for 14 h at 25 °C.

Acknowledgements

The authors thank Mr. Andrew W. Gibbs for his excellent technical assistance, Mrs. Julie Hayward for proofreading the manuscript, NuCana for the financial support to the project and the European Union for financing the stay of R.D.B. at Cardiff University under the ERASMUS student exchange programme. Also, we wish to thank Prof. Maura Marinuzzi, the Erasmus Coordinator at the Department of Pharmaceutical Sciences of Perugia University.

Conflict of Interest

The authors declare no conflict of interest.

Keywords: 2'-deoxypseudoisocytidine · anticancer · C-nucleosides · phosphoramidates · prodrugs

- [1] E. De Clercq, *J. Med. Chem.* **2016**, *59*, 2301.
- [2] F. F. Davies, F. W. Allen, *J. Biol. Chem.* **1957**, *227*, 907.
- [3] G. E. Gutowski, M. J. Sweeney, D. C. DeLong, R. L. Hamill, K. Gerzon, R. W. Dyke, *Ann. N. Y. Acad. Sci.* **1975**, *255*, 544.
- [4] H. Nishimura, M. Mayama, Y. Komatsu, H. Kato, N. Shimaoka, Y. Tanaka, *J. Antibiot.* **1964**, *17*, 148.
- [5] R. K. Robins, L. B. Townsend, F. Cassidy, J. F. Gerster, A. F. Lewis, R. L. Miller, *J. Heterocycl. Chem.* **1966**, *3*, 110.
- [6] J. H. Burchenal, K. Ciovacco, K. Kalaher, T. Toole, R. Kiefner, M. D. Dowling, C. K. Chu, K. A. Watanabe, I. Wempfen, J. J. Fox, *Cancer Res.* **1976**, *36*, 1520.
- [7] T.-C. Chou, J. H. Burchenal, J. J. Fox, K. A. Watanabe, C. K. Chu, F. S. Phillips, *Cancer Res.* **1979**, *39*, 720.
- [8] M. S. Zedeck, *Biochem. Pharmacol.* **1979**, *28*, 1440.
- [9] P. A. Jones, S. M. Taylor, *Cell* **1980**, *20*, 85.

- [10] T. M. Woodcock, T.-C. Chou, C. T. C. Tan, S. S. Sternberg, F. S. Philips, C. W. Young, J. H. Burchenal, *Cancer Res.* **1980**, *40*, 4243.
- [11] a) C. K. Chu, U. Reichman, K. A. Watanabe, J. J. Fox, *J. Heterocycl. Chem.* **1977**, *14*, 1119; b) A. Matsuda, C. K. Chu, U. Reichman, K. Pankiewicz, K. A. Watanabe, J. J. Fox, *J. Org. Chem.* **1981**, *46*, 3603; c) K. Pankiewicz, A. Matsuda, K. A. Watanabe, *J. Org. Chem.* **1982**, *47*, 485.
- [12] a) J. Lu, N.-S. Li, S. C. Koo, J. A. Piccirilli, *J. Org. Chem.* **2009**, *74*, 8021; b) I. Hirao, M. Kimoto, S.-I. Yamakage, M. Ishikawa, J. Kikuchi, S. Yokoyama, *Bioorg. Med. Chem. Lett.* **2002**, *12*, 1391; c) J. Štambaský, M. Hocek, P. Kočovský, *Chem. Rev.* **2009**, *109*, 6729.
- [13] R. Taylor, P. Kotian, T. Warren, R. Panchal, S. Bavari, J. Julander, S. Dobo, A. Rose, Y. El-Kattan, B. Taubenheim, Y. Babu, W. P. Sheridan, *J. Infect. Public Health* **2016**, *9*, 220.
- [14] a) J. Y. Feng, G. Cheng, J. Perry, O. Barauskas, Y. Xu, M. Fenaux, S. Eng, N. Tirunagari, B. Peng, M. Yu, Y. Tian, Y.-J. Lee, G. Stepan, L. L. Lagpacan, D. Jin, M. Hung, K. S. Ku, B. Han, K. Kitrinis, M. Perron, G. Birkus, K. A. Wong, W. Zhong, C. U. Kim, A. Carey, A. Cho, A. S. Ray, *Antimicrob. Agents Chemother.* **2014**, *58*, 1930; b) A. Cho, L. Zhang, J. Xu, R. Lee, T. Butler, S. Metobo, V. Aktoudianakis, W. Lew, H. Ye, M. Clarke, E. Doerffler, D. Byun, T. Wang, D. Babusis, A. C. Carey, P. German, D. Sauer, W. Zhong, S. Rossi, M. Fenaux, J. G. McHutchison, J. Perry, J. Feng, A. S. Ray, C. U. Kim, *J. Med. Chem.* **2014**, *57*, 1812.
- [15] H. K. Bhatia, H. Singh, N. Grewal, N. K. Natt, *J. Pharm. Pharmacother.* **2014**, *5*, 278.
- [16] A. S. Ray, M. W. Fordyce, M. J. M. Hitchcock, *Antiviral Res.* **2016**, *125*, 63.
- [17] a) M. Slusarczyk, M. Huerta Lopez, J. Balzarini, M. Mason, W. G. Jiang, S. Blagden, E. Thompson, E. Ghazaly, C. McGuigan, *J. Med. Chem.* **2014**, *57*, 1531; b) S. Blagden, A. Sukumaran, C. Gnanaranjan, V. Woodcock, M. Slusarczyk, M. Serpi, D. Harrison, M. Middleton, H. Gabra, E. Ghazaly, *J. Clin. Oncol.* **2016**, *34* (suppl), abstr 5565.
- [18] C. McGuigan, P. Murziani, M. Slusarczyk, B. Gonczy, J. Vande Voorde, S. Liekens, J. Balzarini, *J. Med. Chem.* **2011**, *54*, 7247.
- [19] K. Lalitha, K. Muthusamy, Y. S. Prasad, P. K. Vemula, S. Nagarajan, *Carbohydr. Res.* **2015**, *402*, 158.
- [20] O. Boutoureira, M. I. Matheu, Y. Díaz, S. Castellón in *Chemical Synthesis of Nucleoside Analogues* (Ed.: P. Merino), John Wiley & Sons Inc., Hoboken, **2013**, p. 263.
- [21] a) I. Arai, G. D. Daves, *J. Org. Chem.* **1978**, *43*, 4110; b) I. Arai, G. D. Daves, *J. Org. Chem.* **1979**, *44*, 21; c) G. D. Daves, *Acc. Chem. Res.* **1990**, *23*, 201; d) D. L. Kwok, R. N. Farr, G. D. Daves, *J. Org. Chem.* **1991**, *56*, 3711; e) H.-C. Zhang, M. Brakta, G. D. Daves, *Nucleosides Nucleotides* **1995**, *14*, 105.
- [22] A. Mayer, A. Haberli, C. J. Leumann, *Org. Biomol. Chem.* **2005**, *3*, 1653.
- [23] J. Krim, C. Grünwald, M. Taourirte, J. W. Engels, *Bioorg. Med. Chem.* **2012**, *20*, 480.
- [24] E. Larsen, P. T. Jørgensen, M. A. Sofan, E. B. Pedersen, *Synthesis* **1994**, *10*, 1037.
- [25] M. A. Cameron, S. B. Cush, R. P. Hammer, *J. Org. Chem.* **1997**, *62*, 9065.
- [26] M. Serpi, K. Madela, F. Pertusati, M. Slusarczyk, *Curr. Protoc. Nucleic Acid Chem.* **2013**, *53*, 15.5.1–15.5.15.
- [27] B. K. Snell, *J. Chem. Soc. C* **1968**, 2358.
- [28] V. Ferrari, M. Serpi, C. McGuigan, F. Pertusati, *Nucleosides Nucleotides Nucleic Acids* **2015**, *34*, 799.
- [29] a) Y. L. Jiang, J. T. Stivers, *Tetrahedron Lett.* **2003**, *44*, 85; b) Y. L. Jiang, J. T. Stivers, *Tetrahedron Lett.* **2003**, *44*, 4051.
- [30] V. Bou, J. Vilarrasa, *Tetrahedron Lett.* **1990**, *31*, 567.
- [31] M. Derudas, D. Carta, A. Brancale, C. Vanpouille, A. Lisco, L. Margolis, J. Balzarini, C. McGuigan, *J. Med. Chem.* **2009**, *52*, 5520.
- [32] G. Birkus, R. Wang, X. Liu, N. Kutty, H. MacArthur, T. Cihlar, C. Gibbs, S. Swaminathan, W. Lee, M. McDermott, *Antimicrob. Agents Chemother.* **2007**, *51*, 543.
- [33] Y. Satoh, Y. Katoda, Y. Oheda, J. Kuwahara, S. Aikawa, F. Matsuzawa, H. Doi, T. Aoyagi, H. Sakuraba, K. Itoh, *J. Antibiot.* **2004**, *57*, 316.

Received: January 25, 2017


Published online on ■ ■ ■, 2017

FULL PAPERS

M. Serpi,* R. De Biasi, F. Pertusati,
M. Slusarczyk, C. McGuigan



Synthetic Approaches for the Preparation of Phosphoramidate Prodrugs of 2'- Deoxypseudoisocytidine



C the difference: 2'-Deoxypseudoisocytidine is a C-nucleoside with antileukemic activity. A series of phosphoramidate prodrugs of this C-nucleoside were synthesized. Their synthesis proved challenging due to unexpected side reactions (double phosphorylation and epimerization). Their enzymatic activation was found to be similar to that of N-linked nucleoside ProTides.